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EXECUTIVE SUMMARY 
Background: Trends in the nonmedical use of prescription opioids (NMUPO) have been rising in the past few decades, 
causing increases in morbidity and mortality due to prescription opioids (POs). There is some evidence that NMUPO and 
PO dependence (POD) is correlated to the use of heroin, as well as some evidence that the rise in NMUPO may be linked 
to the increases in opioid prescribing seen in the past couple of decades. Despite increasing concerns, however, there has 
been no previous systematic review of the prevalence of POD.  
 
Aims: This study will examine the prevalence of NMUPO and POD globally, with the additional aim of contributing to the 
Global Burden of Disease (GBD) 2016 study dataset. The objectives of this paper are: 
1. To conduct a systematic review of peer-reviewed journal databases to create an updated dataset on the prevalence 
of global opioid use and dependence. 
2. To estimate the global prevalence of POD and to identify the distribution of POD. 
 
Methods: A systematic literature review was performed of the Medline, Embase and PsycINFO databases, and data on the 
prevalence of illicit and PO nonmedical use and dependence by country were extracted. For countries with data on 
prevalence of NMUPOs, but with no data on dependence, the prevalence of POD was calculated using the meta-analysis 
cross-walk adjustment method employed by the GBD study. To do this, a ratio between NMUPOs and POD was calculated 
using data from studies with both parameters available. This ratio was applied to data with only NMUPO prevalence 
available, and used to obtain POD prevalence data. All known and imputed POD prevalence data was then used to 
extrapolate and map regional and super-regional estimates of POD prevalence, weighted on population sizes. 
 
Results: The search resulted in 61376 citations. After title and abstract screening, there were 32 studies from which data 
was extracted and included in this review. The United States (US) had the most data available on POs, with more than half 
the data available from this country.  The highest prevalence of POD reported was 3.4% from a German study. The meta-
analysis resulted in a cross-walk risk ratio (RR) of 0.19 for application to NMUPO prevalence data to obtain estimates of 
POD prevalence. The region with the highest estimated POD weighted prevalence was Western Europe (3.77%), while the 
region with the lowest estimate was Australasia (0.89%). The overall super-regional estimate of prevalence of POD for the 
High Income Super-region (HIS) was 2.43% (1.92 – 3.13%). 
 
Conclusion:  This study has found prevalences of POD of up to 3.4% in high-income regions, and these increasing trends 
are of increasing concern. However, the prevalence of POD is not able to be mapped globally given the current lack of data 
in many regions of the world. This calls for more research to include POD in their monitor of drug dependence in all regions 
of the world, as this potentially poses a large burden on the community given its deadly nature. The timely implementation 
of cost-effective and efficacious prevention and intervention strategies may be able to save much morbidity and mortality. 
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1. INTRODUCTION  
The nonmedical use of prescription opioids (NMUPOs) has been rising globally within the past few decades, particularly in 
the United States (US) (1), where in 2010, NMUPO was second only to cannabis use (2). There is some evidence of the 
burden of disease (BOD) posed by the rise of NMUPO (3), but traditional research so far has focused on heroin use and 
dependence as opposed to prescription opioid (PO) use and dependence (2). NMUPO and PO dependence (POD) have 
been recognized as potentially serious concerns, with parallel rises in morbidity and mortality due to POs, engendering large 
socioeconomic burdens. NMUPO cost the US approximately US$53.4 billion in 2006 (3). An increase in opioid prescribing 
by health practitioners has been linked to rising trends in the NMUPO, which in turn leads to increases in opioid overdose 
(4). The misuse of prescription medications has been shown to be associated with the misuse of illicit drugs (5), and NMUPO 
is also thought to lead to opioid dependence and subsequently abuse of illicit substances, such as heroin (6), thereby 
potentially acting as a “gateway” drug. Despite the rising trends and increasing concerns, however, the prevalences of 
NMUPO and POD have not previously been systematically elicited on a global level. This paper aims to systematically 
elucidate the global prevalences of NMUPO and POD. It is hoped that the knowledge gained will help to build a good 
evidence base from which to better inform prevention and treatment programs in areas of high prevalence. 
  
1.1 Prescription Opioids 
POs are a restricted class of analgesic medications used predominantly for the treatment of moderate to severe pain in 
cancer patients and, increasingly, in non-cancer, chronic pain patients. Opioids are a highly addictive class of substances 
because of their pleasurable psychological effects via activation of the brain’s reward-pathway, mediated by dopamine in 
the ventral tegmental area (among others) of the brain (7). However, opioids also have a large number of significant 
associated harms, even resulting in death due to respiratory depression when taken in large doses, or by opioid-naïve 
patients. 
 
The NMUPOs occurs when individuals take opioids for the pleasurable side-effects rather than pain relief, and the problems 
begin when physiological tolerance (the development of neurological compensatory mechanisms to reduce effects on the 
reward-pathway of the brain) occurs (7). This causes the user to take increasing amounts of POs to gain the same euphoric 
effect, leading to a dysfunctional need for the substance and the development of PO use disorders and POD (see Methods 
section for definitions).  
 
1.2 Morbidity and Mortality 
The prevalence of POD varies, depending on the study, country and sociodemographic profile of the sample population. 
Opioid dependence is gaining recognition as a significant cause of morbidity and mortality in various countries around the 
world, particularly in North America, Eastern Europe and Australia (8). There has been a greater than 30% increase in 
deaths between 2005 and 2015 globally due to substance use, and mortality analysis of the Global Burden of Disease 
(GBD) 2015 study shows that more than 70% of all substance use disorder (SUD) deaths were caused by opioids. Opioid 
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related deaths alone increased by almost a third (29.6%) in the same timeframe, resulting in approximately 122,100 deaths 
in 2015 (9). 
 
In Europe, Arendt et al (2011) showed that, among those with (SUD), mortality rates were highest for those who used heroin 
or illegally obtained POs (10), while a study by Casati et al (2012) revealed that opioids were one of the main groups of 
“misused medications” in Europe (11). In the United States of America (US), among prescription medications, POs are the 
most commonly misused group according to a subnational study done by Currie et al (2011). This same study showed the 
prevalence of NMUPOs in the US as 8.2% in 2002 and rising (5). Collaborating authors of the GBD study have also called 
attention to the increasing mortality in the US due to substance abuse, of which approximately a third is attributable to POs 
(12). The US Centers for Disease Control and Prevention have named POs as the “fastest growing drug problem” in the 
US and state that, from 2003, mortality related to POs in the US is greater than mortality due to heroin and cocaine combined 
(13).  Across the border in Canada, NMUPO was 4.8% in 2009 (3) and increasing. Another study revealed that 15.5% of 
Ontario students used POs non-medically, with 5.9% prevalence in the adult population (2) in more recent years.  
 
Asia – the first and main producer of the original poppy plant from which addictive opium was first derived – is not to be 
forgotten with regards to opioid use (7). Dargan and Wood (2012) states that more than 50% of “the world’s opioid using 
population lives in Asia” (14). It has previously been difficult to elicit accurate data in Asia, but recent improvements in data 
collection programs by the United Nations Office of Drugs and Crime have made prevalence estimates more reliable. 
Dargan and Wood (2012) states that Afghanistan has a 2.7% prevalence of opioid use annually, and is the highest in the 
world, followed by Iran at 2.3% prevalence. There is as yet no opioid use prevalence data for China and India – two large 
populations known to use opioids non-medically – leaving large gaps in the current Asian data. There is, however, a study 
done in Punjab, India, estimating the numbers of opioid dependent people within the Indian state, using respondent driven 
sampling of opioid dependent persons and a multiplier method (15). The study is not as robust as may be desired, however, 
and no final estimate of opioid dependence, as a percentage of the population, is given in the paper. An estimate of 232,856 
opioid dependent individuals within the state is quoted as the result of the study.  
 
1.3 Socio-demographics  
Sociodemographic characteristics of PO users also vary and may be associated with risk of NMUPO and POD. A study by 
Shield et al (2013) revealed a significant association between NMUPO and age (3): younger people were more likely to 
engage in NMUPO than those in older age groups. Di Bona et al (2014) showed differing rates of substance use risk 
behaviours in a study of school students, dependent on race, gender and age, with males and older students being more 
likely to engage in illicit substance use (16). Benavides et al (2013) revealed that unemployment increased the risk of illicit 
substance use (17). Currie et al (2011) showed that disabled status is a strong predictor of prescription medication misuse, 
likely due to the higher numbers of medications usually prescribed to this population. This study also showed that the odds 
of misuse increased for adults with “student” status or a high school diploma, compared to those with a university degree 
(5). It was theorized that university students may use POs as a way to relieve stress, and that those with tertiary qualifications 
were more likely to see a doctor and request treatment. A school-based study found rural students at higher risk of substance 
use (particularly NMUPO) compared to those in urban areas (18). Interestingly, some studies have found that “married” 
status (ie. being married) decreases risk of substance use (19-22). 
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1.4 Effect of Harm Reduction  
One of the more serious concerns of NMUPO is its significant correlation to heroin use, demonstrated by Ihongbe and 
Masho (2016) (6). The same study also showed that the odds of using heroin were highest in the NMUPO group. The high 
burden placed on society by heroin use and dependence is not to be underestimated, and the timely implementation of 
harm reduction strategies in the form of prevention and treatment programs can prevent much suffering and even death. 
The collaborating authors of the GBD have noted that there is an “inverse pattern” between the intensity of harm reduction 
strategies and excess mortality (12). Australia, which has the highest number of and “most intense” interventions (eg. opioid 
substitution therapy (OST) and needle exchange programs), also has the lowest excess mortality due to opioid overdose. 
Eastern European countries with high prevalence have few interventions and high excess mortality. A study by Degenhardt 
et al (2011) showed that users not in treatment had a higher mortality risk than those in current treatment (23). Therefore, 
the benefits of intervention programs are significant and multiple, and should be implemented in areas where there are high 
burdens of illicit opioid use, NMUPO and POD. 
 
1.5 Global Burden of Disease Study and the Sustainable Development Goals 
The Global Burden of Disease (GBD) study is the most comprehensive worldwide epidemiological study on 315 diseases 
and injuries. It is an ongoing, international, observational study depicting the morbidity and mortality of numerous 
communicable and non-communicable diseases across many nations, and generating comparable data with the use of 
standardised tools (8, 24). The study estimates disease burden with the use of a combination of years of life lost (YLL) and 
years lived with disability (YLD), known as the disability adjusted life year (DALY). The measure of the DALY was developed 
in conjunction with the World Bank in the 1990s, and is a means of combining the health and economic effects of diseases 
(25). Analysis of the GBD 2015 study found that both total DALY’s and age-standardised DALY rates due to opioid use 
disorders (OUD) increased substantially between 1990 and 2015, with OUD named a “growing health threat” by international 
experts in the field (8). However, the GBD 2015 study results for OUDs are heavily focused on heroin dependence, as this 
has had a higher burden of disease historically. There remains no systematic data on the prevalence of POD across the 
world. 
 
The estimation of disease burden via DALYs caused mental disorders, including substance dependence, to gain recognition 
as a significant cause of economic and social loss. This recognition of mental health disease as a significant problem globally 
resulted in the inclusion of substance dependence into the Sustainable Development Goals (SDGs) 2015 (12, 24). Goal 3, 
target 3.5 states “strengthen the prevention and treatment of substance abuse, including narcotic drug abuse and harmful 
use of alcohol” (emphasis added) (24), with specific indicators for intervention needs. This recognition and incorporation 
into the international SDGs acknowledges that there is an urgent need for effective, cost-efficient interventions and – in 
conjunction with this – a good understanding of where the BOD of substance dependence lies globally. Much of the current 
data on opioid use is focused on illicit use, ie. heroin use. However, there is a lack of systematic research conducted on 
NMUPO and POD to date. The intent of this project is to help fill in the present gap in epidemiological knowledge by mapping 
the prevalence of POD globally, thereby contributing to the development of evidence-based programs and interventions. 
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1.6 Aims and Rationale 
Eliciting and presenting the prevalence and patterns of POD globally enables an estimation of its harms, as well as the BOD 
associated with NMUPO and POD, which has effects at individual and community levels: psychologically, physiologically, 
socially and economically.  An estimation of disease burden can increase the evidence base to aid in the development of 
preventative policies, strategies and programs, at national and local levels, to decrease the prevalence of NMUPO and POD 
(12).  
 
This study will examine the prevalence of NMUPO and POD globally, with the additional aim of contributing to the GBD 
2016 study dataset. The objectives of this paper are: 
1.  To conduct a systematic review of peer-reviewed journal databases to create an updated dataset on the prevalence 
of global opioid use and dependence 
2.  To estimate the global prevalence of POD and to identify its distribution. 
2. METHODS 
 
2.1 Systematic Literature Search  
Ethics approval for this systematic review was gained from the University of Queensland, School of Public Health Ethics 
Committee. Multiple research strategies were utilised, including systematic searches of peer-reviewed literature and 
collaboration with experts in the field.   The choice of databases was selected in concert with expert opinion as well as 
discussion with research librarians. A systematic search of peer-reviewed literature was performed using Medline, Embase 
and PsycINFO databases. The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) style was 
employed (26). 
 
The search for this study was undertaken as a part of the GBD 2016 study on the global prevalence of substance 
dependence, namely cannabis, opioids, cocaine and amphetamines. Only papers pertaining to opioids were selected for 
the present study. Search terms were grouped into: 1. substances; 2. use or dependence; 3. database specific terms 
representing substance dependence (eg. MeSH or Emtree terms); and 4. epidemiology measures (eg. prevalence). Search 
strategy was grouped as ((1 AND 2) OR 3) AND 4. As this search was part of a larger study, total search strings were quite 
extensive and included terms for all substances in the GBD 2016 study. The search strings for the database searchers are 
presented in Appendix 6.1.  
 
Epidemiological search strings were standardised according to those used for the Psychiatric Epidemiology and Burden of 
Disease Group (PEABOD team), of which the researchers were a part. This team researches mental and substance use 
disorders in the GBD study. Search limitations comprise publication year from 2009 onwards (as the last systematic review 
on opioid dependence was conducted in 2009), peer reviewed journal articles and human studies. There were no limits set 
on language as the research team included translators. All stages of screening were performed by two reviewers. Data 
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extraction was conducted simultaneously with full-screen review ie. if an article was selected for inclusion, the data was 
immediately extracted. 
 
2.2 Case Definition 
NMUPO was defined as any use of POs within the past year that did not follow a doctor’s instructions. Each study defined 
NMUPO slightly differently, but most adhered to some variation of the above. POD was defined according to the Diagnostic 
and Statistical Manual (DSM) –IV, DSM-IV TR, DSM 5 or International Classification of Disease (ICD) criteria for opioid 
dependence or OUD.  
 
The DSM-IV TR criteria for substance dependence is a “maladaptive pattern of substance abuse, leading to significant 
impairment or distress”. Within a 12 month period, this must be experienced in conjunction with a minimum of three of the 
following:  
- Tolerance – markedly larger amounts of substance necessary for desired effect OR markedly smaller effect with 
use of same amount of substance 
- Withdrawal – presence of typical withdrawal syndrome for the substance OR substance (or similar substance) taken 
to reduce/avoid withdrawal symptoms 
- regular increase in amount of substance used or duration of use 
- unable to control substance use even when willing 
- much time spent in obtaining or using substance 
- time for other important activities is cut down 
- substance use continued even in the knowledge of persistent physical or psychological problems due to use 
 
These criteria were used to ensure standardisation, comparability and consistency across all selected studies.  
 
2.3 Study Selection and Bias 
The inclusion criteria for this analysis were: utilisation of DSM or ICD criteria (as discussed above) for definition of 
dependence to ensure comparability and quality of data, recall period not more than one year (ie. NMUPO or POD in past 
year), studies with samples that were representative of the general population to decrease bias (eg. hospital data, prison or 
university samples excluded), sufficiently detailed methods section to allow assessment of study quality, and data not 
already captured by another paper already included in the study. Relevant school-based studies were included, given the 
sparsity of general population studies that include individuals under the age of eighteen years. 
 
Recall period was maintained at one year or less to ensure accuracy of results, as it has been shown that “lifetime” recall 
of sample populations may be biased (27). Studies that presented data obtained from non-representative sample 
populations, such as treatment groups, prison inmates, hospital patients, university students etc, were excluded, as 
prevalence estimates from these samples are likely to be over-estimates compared to the general population, and present 
the risk of bias. The number of those using POs non-medically, or who are opioid dependent, is likely to be falsely elevated 
(such as in treatment groups) or falsely depressed in these samples. Students at university often have a different 
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demographic profile to the general population. For this reason, studies including sample populations from these or similar 
groups, which were not deemed to accurately represent the general population of that country/area, were excluded. Due to 
these strict criteria, as well as to the definitions of nonmedical use (NMU) and dependence used, study results are 
comparable and the risk of bias within and across individual studies has been minimised. 
 
2.4 Data Extraction 
Data was extracted according to the Institute for Health Metrics and Evaluation (IHME) data extraction sheet for the GBD 
datasets. Data variables of interest included drug type, use or dependence, country, population representativeness, study 
details (eg. year, type), sample population demographics, and relevant statistics (eg. sample size, prevalence, confidence 
intervals, standard error). For this paper, only studies focusing on the prevalence of opioid NMU, opioid dependence, 
NMUPO and POD were selected for analysis. 
 
2.5 Level of Recommendation of Included Studies 
The National Health and Medical Research Council (NHMRC) of Australia “Grades of Recommendation” (28) was used to 
classify the studies selected in this paper (see Table 1). The levels of recommendation assigned to different types of sources 
were as follows:  
A: peer-reviewed published literature with strong evidence base and rigorous methods eg. Journal articles 
B: non-peer-reviewed trusted sources eg. Reports from internationally-recognised or intergovernmental agency reports eg. 
UN or WHO reports, government reports 
C: conference abstracts, technical reports 
D: seminars, presentations, opinion, non-peer-reviewed research with unclear methods 
 
Table 1: Definition of NHMRC Grades of Recommendations 
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2.6 Data Analysis 
Data were analysed using Excel and MetaXL packages; MetaXL is an add-in to Excel that supports all major meta-analysis 
methods. The GBD study presents dependence data for all relevant substances. Therefore, the aim of this analysis was to 
estimate POD globally.  
 
2.6.1 Study Characteristics, Descriptive Statistics and Data Availability 
First it is necessary to examine the data that is available for prevalence of opioid and heroin use and dependence in each 
country. All prevalence data for all opioid types in each study were extracted per country location. This data will contribute 
to the GBD 2016 opioid dependence dataset. Location identification was based on the GBD 2015 population datasets (29). 
Countries and territories were each given a level identification of “3”. Countries/territories were grouped into regions, which 
were designated as level “2”. These regions were then grouped into super-regions and given a level “1” identification (See 
Appendix 6.2). 
 
2.6.2 Estimating a Cross-walk Ratio from Nonmedical Use to Dependence for Prescription Opioids 
The aim of this study is to estimate the global prevalence of POD. However, there may be some countries that only have 
data on NMUPO. Therefore, it may be necessary to estimate dependence data from NMU only data. For this paper, POD 
estimates will be calculated using the cross-walk method utilised by the GBD study (12). This method employs a cross-walk 
meta-analysis to obtain a ratio between NMU and dependence from original data containing both variables. This ratio will 
then be applied to data that has only NMU data available.  
 
Studies with data for both PO NMU and dependence were used for the cross-walk meta-analysis using a random effects 
model forest plot. The standard error of the mean (SE) will be required for these calculations; if a study does not supply the 
SE, it will be calculated using the standard formula: (SE) = square root (prevalence * (1 – prevalence) / sample size). For 
the purposes of this analysis, DSM-IV or DSM-5 diagnosed prescription opioid use disorder (POUD) will be placed into the 
same category as POD. This is consistent with the changes made to DSM-5, which integrates POUD into the diagnosis of 
PO dependence (30). A risk ratio (RR) with 95% confidence intervals will be estimated for POD compared to NMUPO for 
each study, then pooled by conducting meta-analyses. Cochrane’s Q tests and I2 index will be used to assess heterogeneity. 
 
2.6.3 Estimation of Prescription Opioid Dependence Based on Data for Prescription Opioid Nonmedical 
Use 
The pooled risk ratio (RR) obtained from the meta-analysis will then be used to “cross-walk” (ie. adjust) known NMUPO 
data to estimated POD data for that country. This will be done by applying the calculated RR to NMU data to obtain POD 
data estimates. The prevalence of POD will be estimated by multiplying the reported PO NMU prevalence with the cross-
walk RR. This will be done for studies with data on PO NMU only, and with no data for POD. 
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2.6.4 Estimation of Regional and Super-Regional Prevalence of Prescription Opioid Dependence  
Country estimates (%) of POD will then applied to regional and super-regional locations. These regional and super-regional 
estimates (%) will be used to calculate estimates of number of population with POD from GBD 2015 country population 
data.  
 
The estimated regional and super-regional prevalence estimates were the mean of available country-level estimates, within 
a region or super-region respectively, weighted by estimated country aged 15-64 years United Nations population size. This 
procedure involves a three-step process. Step one uses available prevalence data within a country to estimate number of 
cases within the country. In countries with data, this will be estimated by multiplying the prevalence (%) in a given country 
with the population size of that country. Step two calculates the weighted prevalence of a region. This is done by first 
obtaining the sum of the estimated number of cases across all countries within the region with available data (calculated 
from step one). This is then divided by the sum of the population sizes of those countries. Step three uses the weighted 
prevalence of a region (calculated from step two) to impute the number of cases in countries with no data within that same 
region, which are summed to estimate the cases in the regions.  
 
These steps will be performed for each of the regions for which POD was estimated. If a region does not have any country 
with data, this region will be excluded from the above extrapolation process. Super-regional estimates will be extrapolated 
from regional estimates. The Tableau data visualization package will be used to globally map the population estimates 
obtained for regional and super-regional locations with data. 
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3. RESULTS 
3.1 Search Results 
Systematic database searches returned the following: PsycINFO 12,180 results; Medline 18,930 results and Embase 
30,266 results (see Figure 1). A further 17 resources were identified through expert collaboration and hand searches. After 
removal of duplicates, 46615 articles remained for screening. The number of records excluded in the title screen was 42459. 
Abstract screen removed a further 3574 papers, with 600 records identified for full-screen review. During full-screen review, 
papers were excluded if: data was already captured, such as same data already extracted from another paper or study (n 
= 43), sample was biased and did not meet the sample representativeness inclusion criteria (n = 50), no usable data in the 
paper (n = 76), no data on opioids use or opioids dependence (n = 327), paper was a commentary or no original empirical 
data (n = 37), recall period more than one year, e.g. lifetime prevalence (n = 35) (see Figure 1). Due to the inclusion of ALL 
four drugs (cannabis, cocaine and amphetamines, as well as opioids) relevant to the GBD study during the systematic 
database search, the search returned a high number of records. Similarly, the high number of records excluded in the full 
text screen is also due to the exclusion of articles pertaining to one of the other drugs. There was a total of 32 studies 
included in the final analysis, with eight studies with data on POD and 19 studies on NMUPO. 
3.2 Evidence of Nonmedical Use and Dependence from the Systematic Review 
A summary of the studies extracted after screening is presented in Table 2. Please see section 2.6.1 above and Appendix 
6.2 for explanation of location identification, which is based on the GBD study. There were four studies with data for any 
opioid NMU, and one study for any opioid dependence. NMUPO had the most data extracted from a total of 19 studies. 
There were six studies that presented data for both NMUPO and POD, with a further two studies on PO dependence alone. 
There were two studies with heroin use data, and two studies with heroin dependence data. Eight of the above studies 
included data from school surveys. NB. The numbers given above are not exclusive of one another and some studies 
contained more than one type of data. 
 
Table 3 below presents all the data extracted from the included studies. A complete list of the studies in Table 3 can be 
found in Appendix 6.3. There are a total of 114 data-points extracted from 32 sources. All data presented are for both sexes 
combined, ie. there is no stratification for sex. This is due to paucity of included studies that have stratified data by sex. The 
highest prevalence of POD is 3.4% in Germany (Pabst et al, 2013), with the lowest prevalence in the US at 0.2% (Boyd et 
al, 2009). The highest prevalence of opioid use is in Germany (Pabst et al, 2013) with 61.9% use. However, this value is 
very high and this “use” is likely use of any analgesic/PO, including medical use of POs (31). Therefore, this data-point is 
excluded from further analysis. The second highest prevalence of NMUPO is in Spain (Aguilar-Palacio et al, 2014) with 
23.3%.  
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Figure 1: PRISMA Flow Diagram for study inclusion 
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The third highest prevalence of NMUPO is 15.5% in Canada (Fischer et al, 2013), but it must be noted that this age range 
is a younger demographic of 15-18 year olds. All extracted NMUPO prevalences around 10% have a younger age group 
for the sample, and are usually school-based samples. While this is representative for this age range, it is not representative 
of the general population as a whole, and could skew the results. Therefore, the next highest prevalence of NMUPO selected 
for a more representative age range (12-99 years) is 7.7% in the US (Back et al, 2010). The lowest prevalence of NMUPO 
is 0.06% in the US (Jones et al, 2016). It is interesting to note that no studies from the United Kingdom had data for extraction 
as per the results of this literature search. 
 
As per the classification in Table 1, only two sources had levels of recommendation other than level A: data from the 
Australian National Drug Strategy Household Survey (NDSHS), which is an Australian government publication (32); and 
data from the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA), which is the leading drug monitoring 
agency for the European Union and an inter-governmental, internationally recognised body (33); both of which had a Grade 
B level of recommendation (28).  
 
Australia only has data for analgesic, buprenorphine and methadone use, available from the NDSHS 2014. The NDSHS 
estimates any PO use in Australia at 3.8%. Many European countries also have only grade B level of recommendation for 
data on any opioid use (Czech Republic), opioid dependence (Slovenia, Latvia, Cyprus, France, Germany, Greece, Malta, 
Norway, Portugal), or heroin dependence (Italy, Spain) from the EMCDDA 2016 (see Table 2).  
 
Egypt is the only country outside of the High Income Super-region to have original NMUPO data available (Bassiony et al, 
2015), with a POD prevalence of 0.49%. The Southeast Asia, East Asia, and Oceania Super-region only has data on heroin 
use in Thailand available (Wongtongkam et al, 2015), while the Latin America and Caribbean, and the South Asia Super-
regions, have no opioid use or dependence data available from this systematic literature search. The author is aware, 
however, that this may merely be due to language barriers and restriction to peer-reviewed databases (see Limitations 
section).  
 
3.3 Cross-walk Meta-Analysis Using Studies with Prescription Opioid Nonmedical 
Use and Dependence Data 
The most data extracted was for NMUPO (see Table 2 below). However, this project focuses on POD. Therefore, POD data 
were estimated from NMUPO data, so as to make use of all available data. For this purpose, a cross-walk meta-analysis 
was performed using studies that presented data on both NMU and dependence for POs. This analysis determined a ratio 
between NMUPO and POD, which was then used to convert NMUPO to POD for studies that only presented NMUPO data. 
The series of meta-analyses conducted are presented below, with reasons for arrival at the final cross-walk ratio.  
 
As shown in Table 2, there were only six studies within inclusion criteria that had data for both NMU and dependence of 
POs – Pabst et al, 2013, Back et al, 2010, Bassiony et al, 2015, Han et al, 2015, Martins et al, 2010 and Saha et al, 2016. 
The data from Pabst et al, 2013, however, appears too high for NMUPO (61.9%), and is more likely to be any use of POs 
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and other analgesics, including approved medical use (31). This study was therefore excluded from the analysis as it would 
likely yield invalid results. 
 
Figure 2 below shows the forest plot meta-analysis of the remaining five studies (see Appendix 6.4, Table 7 for complete 
statistics). However, data from Bassiony et al, 2015 appears to be an extreme outlier with a small sample size (n = 204) 
and corresponding low numbers for data values of interest (PO use = 18, PO dependence = 1).  This study was therefore 
excluded from analysis, as it was deemed to be an outlier. 
 
Figure 3 below shows the forest plot of the meta-analysis after removal of the data from Bassiony et al, 2015. There are 
only four studies, but fourteen data points. The Han et al, 2015 study reported data across multiple years and dominates 
the results of the meta-analysis (see Appendix 6.4 for complete statistics). Therefore, only the most recent data from Han 
et al, 2015 was used for analysis, leaving just four data points for analysis.  
 
Finally, Figure 4 below is a forest plot of the analysis of the four remaining eligible studies with only the most recent data 
from Han et al, 2015. The Cochrane’s Q chi-squared test showed statistically significant results, Q=62.12, p<0.001, with 
considerable heterogeneity, I2=95%. Therefore, a random effects model was utilized. The pooled risk ratio (RR), or overall 
RR, obtained is 0.19 (0.14 – 0.25; see Appendix 6.4 for complete statistics). This result was used in the estimation of POD 
from existing NMUPO data for the cross-walk (see Table 4).  
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Table 2: Studies by Type of Opioid Use 
Opioid Use Type Study Name 
Any Opioid Nonmedical Use Peltzer 2010, Zuccato 2016, Lawental 2015, EMCDDA 2016: Czech Republic 
Any Opioid Dependence EMCDDA 2016: Slovenia, Latvia, Cyprus, France, Germany, Greece, Malta, Norway, Portugal 
Prescription Opioid Nonmedical Use Currie 2011, Currie 2012, Schepis 2016, Moore 2009, Biondo 2014, Arterberry 2016, Aguilar-Palacio 2014, Ihongbe 
2016, Fischer 2013, Shield 2011, Shield 2013a, Shield 2013b, Brands 2010, Fiellin 2013, McCabe 2013, Jones 2016, 
Kerridge 2015, Fischer 2010, Catalano 2011 
Prescription Opioid Dependence Boyd 2009, Kraus 2013 
Prescription Opioid Nonmedical Use and 
Dependence 
Han 2015, Bassiony 2015, Martins 2010, Pabst 2013, Saha 2016, Back 2010 
Heroin Use Wongtongkam 2015, Ihongbe 2016 
Heroin Dependence Sopko 2016, EMCDDA 2016: Italy, Spain 
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Table 3: Opioid Use, Nonmedical Use and Dependence per Super-region (1), Region (2) and Country / Territory (3): All Extracted Data. Male and Female 
Combined 
  
    
 
 
USE DEPENDENCE 
 # Location# First Author 
(year) 
Data 
(Y) 
Age 
(Year) 
School 
Survey 
LOR Type 
(O) 
% N Cases SE Type 
(O) 
% N Cases SE 
1 SOUTHEAST ASIA, EAST ASIA, 
AND OCEANIA 
                           
2 East Asia 
 
  nd                        
2 Southeast Asia                            
3 Thailand Wongtongkam 
(2015)  
2011 16-18 Yes A H 1.52% 1778 27 0.41%           
2 Oceania 
 
  nd                        
1 CENTRAL EUROPE, EASTERN 
EUROPE, AND CENTRAL ASIA 
                           
2 Central Asia   nd                        
2 Central Europe                            
3 Czech 
Republic 
EMCDDA (2016)      No B H, M, B <0.01%   11300             
3 Czech 
Republic 
Sopko (2016)  2011 15-65 No A      H 0.21% 6786 14 0.08% 
3 Slovenia EMCDDA (2016)  2013   No B           H, M, 
B, O, 
OST 
<0.01%   5200   
2 Eastern Europe                            
3 Latvia EMCDDA (2016) 2014   No B           O 
(TD) 
<0.01%   6151   
1 HIGH INCOME                            
2 High-income Asia Pacific   nd                        
2 Australasia                            
3 Australia NDSHS (2014)  2013 12-99 No B An, B, M 3.80% 23855 906             
2 Western Europe                            
3 Cyprus EMCDDA (2016) 2014   No B           H, M, 
O 
0.18%   1094   
23 
 
(TD). 
OST  
3 France EMCDDA (2016) 2013-
2014 
  No B           H, M, 
B, O 
(TD) 
<0.01%   211000   
3 Germany Kraus (2013)  2000 18-59 No A           PO 2.25% 8139 183   
3 Germany Pabst (2013)  2012-
2012 
18-64 No A O (not 
H) 
61.90% 9018 5582 0.01% PO 3.40% 9054 308 0.003 
3          Germany Pabst (2013) 2012-
2012 
18-64 No A H 0.20% 9063 18 0.07%           
3 Germany EMCDDA (2016) 2012   No B           H, M, 
B, O 
0.30%   155994   
3 Greece EMCDDA (2016) 2014   No B           H, 
OST 
<0.01%   17245   
3 Israel Lawental (2015)  2012-
2013 
18-40 No A M 0.80% 1200 9             
3 Israel Lawental (2015) 2012-
2013 
18-40 No A O 0.50% 1200 6             
3 Israel Lawental (2015) 2012-
2013 
18-40 No A H 0.40% 1200 5             
3 Italy Zuccato (2016)  2010 15-64 No A O 0.17% 12323 21 0.07%           
3 Italy Zuccato (2016) 2012 15-64 No A O 0.08% 19294 15 0.04%           
3 Italy Zuccato (2016) 2014 15-64 No A O 0.10% 8465 8 0.07%           
3 Italy EMCDDA (2016) 2014   No B           H <0.01%   203000   
3 Malta EMCDDA (2016) 2014   No B           O <0.01%   1614   
3 Norway EMCDDA (2016) 2013   No B           H, M, 
O 
<0.00%   9015   
3 Portugal EMCDDA (2016) 2012   No B           O <0.01%   31858   
3 Spain EMCDDA (2016) 2013   No B           H <0.01%   65648   
3 Spain Aguilar-Palacio 
(2014)  
2006-
2006 
16-65 No A An 23.30% 993 231             
2 Southern Latin America   nd                        
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2 High-income North America                            
3 Canada Currie (2011)  2002 18-99 No A PO 4.90% 3511 172 
  
      
 
3           Canada Currie (2011) 2002 18-99 No  A H 0.10% 3511 3             
3 Canada Fischer (2013)  2011 15-18 Yes A NMUPO  15.50% 3339 518             
3 Canada Fischer (2013) 2011 18-99 No A NMUPO 5.9% 4023 237 
 
          
3 Canada Shield (2011)  2008-
2009 
18-99 No A NMUPO 1.95% 2030 40             
3 Canada Shield (2013b)  2009 15-99 No A NMUPO 4.80% 13082 628             
3 Canada Fischer (2010)  2008 15-99 No A NMUPO 0.50% 16672 83             
3 Canada Shield (2013a)  2008-
2009 
18-99 No A NMUPO 2.00% 2017 40             
3 Canada Shield (2013a)  2010 18-99 No A NMUPO 7.70% 2015 143             
3 Canada Currie (2012)  2008-
2009 
12-18 Yes A An 4.00% 45163 1807             
3 Canada Brands (2010)  2007 12-19 Yes A NMUPO 6.20% 2914 181             
3 US Martins (2010)  2001-
2002 
18-57 No A NMUPO 1.57% 31397 494   POUD 0.40% 31397 127   
3 US Fiellin (2013)  2006-
2008 
18-25 No A NMUPO 11.76% 55215 6496             
3 US Saha (2016)  2012-
2013 
18-99 No A NMUPO 4.10% 36309 1579 0.16 POUD 0.89% 36309 330 0.05 
3 US McCabe (2013)  2009-
2011 
12-18 Yes A NMUPO 7.00% 1928 135             
3 US Han (2015)  2003 18-99 No A NMUPO 5.40% 42700 2306   POUD 0.60% 42700 256   
3 US Han (2015) 2004 18-99 No A NMUPO 5.10% 43100 2198   POUD 0.60% 43100 259   
3 US Han (2015) 2005 18-99 No A NMUPO 5.40% 43300 2338   POUD 0.70% 43300 303   
3 US Han (2015) 2006 18-99 No A NMUPO 5.80% 42100 2442   POUD 0.70% 42100 295   
3 US Han (2015) 2007 18-99 No A NMUPO 5.70% 42700 2434   POUD 0.80% 42700 342   
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3 US Han (2015) 2008 18-99 No A NMUPO 5.30% 43200 2290   POUD 0.80% 43200 346   
3 US Han (2015) 2009 18-99 No A NMUPO 5.60% 43000 2408   POUD 0.90% 43000 387   
3 US Han (2015) 2010 18-99 No A NMUPO 5.50% 43300 2382   POUD 0.90% 43300 390   
3 US Han (2015) 2011 18-99 No A NMUPO 4.90% 43600 2136   POUD 0.80% 43600 349   
3 US Han (2015) 2012 18-99 No A NMUPO 5.60% 42900 2402   POUD 1.00% 42900 429   
3 US Han (2015) 2013 18-99 No A NMUPO 4.90% 42400 2078   POUD 0.90% 42400 382   
3 US Jones (2016)  2006 12-99 No A NOU 0.50% 67500 338 0.04           
3 US Jones (2016) 2007 12-99 No A NOU 0.60% 67400 404 0.04           
3 US Jones (2016) 2008 12-99 No A NOU 0.06% 67900 41 0.04           
3 US Jones (2016) 2009 12-99 No A NOU 0.70% 68000 476 0.04           
3 US Jones (2016) 2010 12-99 No A NOU 0.70% 67800 475 0.05           
3 US Jones (2016) 2011 12-99 No A NOU 0.60% 70100 421 0.04           
3 US Jones (2016) 2012 12-99 No A NOU 0.60% 68300 410 0.04           
3 US Jones (2016) 2013 12-99 No A NOU 0.50% 67800 339 0.05           
3 US Schepis (2016)  2002-
2003 
50-99 No A NMPDU 1.00% 9793 98             
3 US Schepis (2016) 2012-
2013 
50-99 No A NMPDU 1.70% 12696 216             
3 US Moore (2009)  2001-
2002 
65-99 No A NMUPO 0.50% 7964 40             
3 US Kerridge (2015)  2012-
2013 
18-99 No A           POUD 0.90% 36667 330   
3 US Catalano (2011)  2003-
2004 
15-17 Yes A NMUPO 12.30% 846 104             
3 US Back (2010)  2006 12-99 No A PO 7.74% 55279 4281   POUD 1.03% 55279 568   
3 US Boyd (2009)  2004-
2005 
18-99 No A           PO 0.20% 33158 62 <0.1% 
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3 US Biondo (2014)  2005 17-19 Yes A NMUPO 9.00% 15127 1361             
3 US Biondo (2014) 2006 17-19 Yes A NMUPO 9.00% 15127 1361             
3 US Biondo (2014) 2007 17-19 Yes A NMUPO 9.20% 15127 1392             
3 US Biondo (2014) 2008 17-19 Yes A NMUPO 9.10% 15127 1377             
3 US Biondo (2014) 2009 17-19 Yes A NMUPO 9.20% 15127 1392             
3 US Biondo (2014) 2010 17-19 Yes A NMUPO 8.70% 15127 1316             
3 US Biondo (2014) 2005 17-19 No A NMUPO 12.50% 3020 378             
3 US Biondo (2014) 2006 17-19 No A NMUPO 12.80% 3020 387             
3 US Biondo (2014) 2007 17-19 No A NMUPO 10.10% 3020 305             
3 US Biondo (2014) 2008 17-19 No A NMUPO 12.80% 3020 387             
3 US Biondo (2014) 2009 17-19 No A NMUPO 10.80% 3020 326             
3 US Biondo (2014) 2010 17-19 No A NMUPO 9.80% 3020 296             
3 US Arterberry (2016)  2001-
2005 
18-99 No A NMUPO 1.58% 34,649 547             
3 US Ihongbe (2016)  2011-
2013 
18-25 No A H 0.73% 55,940 408             
3 US Ihongbe (2016) 2011-
2013 
18-25 No A O 9.60% 55940 5370             
1 LATIN AMERICA AND CARIBBEAN 
  
 
           
2 Caribbean   nd                        
2 Andean Latin America   nd                        
2 Central Latin America   nd                        
2 Tropical Latin America   nd                        
1 NORTH AFRICA AND MIDDLE 
EAST 
                           
2 North Africa and Middle East                            
3 Egypt Bassiony (2015)  2013 12-17 Yes A PO 8.80% 204 18   PO 0.49% 204 1   
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1 SOUTH ASIA                             
2 South Asia   nd                        
1 SUB-SAHARAN AFRICA                            
2 Central Sub-Saharan Africa   nd                        
2 Eastern Sub-Saharan Africa   nd                        
2 Southern Sub-Saharan Africa                            
3 South Africa Peltzer (2010)  2008 15-99 No A O 0.50% 13828 69             
2 Western Sub-Saharan Africa   nd                        
#  Location identification as per GBD (2015). 1 = Super-region, 2 = Region, 3 = Country / Territory  
N = Sample Size, SE = Standard Error, nd = no data, Y = year      
LOR = Level of Recommendation         
A = peer reviewed journal article. B = Published book / international governmental monitoring organisation report / government report 
O = Opioids, PO = Prescription Opioids, H = Heroin, M = Methadone, B = Buprenorphine, An = Analgesics, C = Codeine 
OST = opioid substitution therapy, (TD) = Treatment Data      
NMUPO = Nonmedical Use of Prescription Opioids, NOU = Nonmedical Oxycontin Use   
NMPDU = Nonmedical Prescription Drug Use, POUD = Prescription opioid use disorder  
EMCDDA = European Monitoring Centre for Drugs and Drug Addiction, NDSHS = National Drug Strategy Household Survey 
NESARC = National Epidemiologic Survey of Alcohol and Related Conditions Waves I and II, NESARC III = NESARC Wave III  
OHDUHS = Ontario Student Drug Use and Health Survey, CAMH = Centre for Addiction and Mental Health, NSDUH = National Survey on Drug Use and Health 
CADUMS= Canadian Alcohol and Drug Use Monitoring Survey, YSS = Youth Smoking Survey, SSLS = Secondary Student Life Survey  
RHC = Raising Healthy Children, MTF = Monitoring the Future     
SABSSM = South African National HIV Incidence, Prevalence, Behaviour and Communication Survey 
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Figure 2: Meta-Analysis All Studies with Nonmedical Use and Dependence Data (Pabst 2013 Excluded) 
  
PrescriptionOpioidDep/PrescriptionOpioidUse_Random effects
RR
0.320.310.30.290.280.270.260.250.240.230.220.210.20.190.180.170.160.150.140.130.120.110.10.09
Study 
Han (2015), United States, age 18-99, year 2003 
Han (2015), United States, age 18-99, year 2004 
Han (2015), United States, age 18-99, year 2006 
Han (2015), United States, age 18-99, year 2005 
Back (2010), United States, age 12-99, year 2006 
Han (2015), United States, age 18-99, year 2007 
Han (2015), United States, age 18-99, year 2008 
Overall 
Q=152.09, p=0.00, I2=91%
Han (2015), United States, age 18-99, year 2009 
Han (2015), United States, age 18-99, year 2011 
Han (2015), United States, age 18-99, year 2010 
Han (2015), United States, age 18-99, year 2012 
Han (2015), United States, age 18-99, year 2013 
Saha (2016), United States, age 18-99, year 2012-13 
Martin (2010), United States, age 18-57, year 2001-02 
    RR (95% CI)          % Weight
   0.11  (  0.10,  0.13)      7.04
   0.12  (  0.10,  0.13)      7.04
   0.12  (  0.11,  0.14)      7.13
   0.13  (  0.12,  0.15)      7.15
   0.13  (  0.12,  0.14)      7.47
   0.14  (  0.13,  0.16)      7.22
   0.15  (  0.13,  0.17)      7.22
   0.15  (  0.14,  0.17)    100.00
   0.16  (  0.14,  0.18)      7.28
   0.16  (  0.15,  0.18)      7.22
   0.16  (  0.15,  0.18)      7.28
   0.18  (  0.16,  0.20)      7.33
   0.18  (  0.16,  0.20)      7.26
   0.21  (  0.19,  0.24)      7.16
   0.26  (  0.21,  0.31)      6.19
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Figure 3: Meta-Analysis Without Egyptian Study (Bassiony, 2015) Data 
  
PrescriptionOpioidDep/PrescriptionOpioidUse_Random effects
RR
0.420.40.380.360.340.320.30.280.260.240.220.20.180.160.140.120.10.080.060.040.020
Study 
Bassiony (2015), Egypt, age 12-99, year 2013 
Han (2015), United States, age 18-99, year 2003 
Han (2015), United States, age 18-99, year 2004 
Han (2015), United States, age 18-99, year 2006 
Han (2015), United States, age 18-99, year 2005 
Back (2010), United States, age 12-99, year 2006 
Han (2015), United States, age 18-99, year 2007 
Han (2015), United States, age 18-99, year 2008 
Overall 
Q=153.06, p=0.00, I2=91%
Han (2015), United States, age 18-99, year 2009 
Han (2015), United States, age 18-99, year 2011 
Han (2015), United States, age 18-99, year 2010 
Han (2015), United States, age 18-99, year 2012 
Han (2015), United States, age 18-99, year 2013 
Saha (2016), United States, age 18-99, year 2012-13 
Martin (2010), United States, age 18-57, year 2001-02 
    RR (95% CI)          % Weight
   0.06  (  0.01,  0.41)      0.26
   0.11  (  0.10,  0.13)      7.02
   0.12  (  0.10,  0.13)      7.02
   0.12  (  0.11,  0.14)      7.12
   0.13  (  0.12,  0.15)      7.13
   0.13  (  0.12,  0.14)      7.45
   0.14  (  0.13,  0.16)      7.20
   0.15  (  0.13,  0.17)      7.20
   0.15  (  0.14,  0.17)    100.00
   0.16  (  0.14,  0.18)      7.26
   0.16  (  0.15,  0.18)      7.20
   0.16  (  0.15,  0.18)      7.27
   0.18  (  0.16,  0.20)      7.31
   0.18  (  0.16,  0.20)      7.24
   0.21  (  0.19,  0.24)      7.14
   0.26  (  0.21,  0.31)      6.17
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Figure 4: Meta-Analysis with Only Most Recent Data from Han (2015) Study 
 
  
PrescriptionOpioidDep/PrescriptionOpioidUse_Random effects
RR
0.30.250.20.15
Study 
Back (2010), United States, age 12-99, year 2006 
Han (2015), United States, age 18-99, year 2013 
Overall 
Q=62.12, p=0.00, I2=95%
Saha (2016), United States, age 18-99, year 2012-13 
Martin (2010), United States, age 18-57, year 2001-02 
    RR (95% CI)          % Weight
   0.13  (  0.12,  0.14)     25.88
   0.18  (  0.16,  0.20)     25.49
   0.19  (  0.14,  0.25)    100.00
   0.21  (  0.19,  0.24)     25.30
   0.26  (  0.21,  0.31)     23.32
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3.4 Application of the Cross-walk Results to Estimate Prevalence of Prescription 
Opioid Dependence.  
Using the pooled RR from the random effects model meta-analysis above (see Figure 4), NMUPO data are “cross-
walked” to POD estimates, i.e. POD data are calculated using NMUPO data. Upper and lower 95% confidence intervals 
(CIs) are also calculated and shown. To present all data available on POD, all original POD / POUD data and calculated 
95% CIs are presented in Table 4 below, as well as all estimated POD data from NMUPO data using the pooled RR of 
0.19. Data from the EMCDDA study is not presented for further analysis because much of the data comes from treatment 
populations and there is insufficient detail on the methods of data collection available (33). 
 
The highest estimate of POD is 4.39% in Spain (Aguilar-Palacio et al, 2014). The lowest estimate is 0.01% in the US (Jones 
et al, 2016). The US has fifteen studies with original or estimated dependence data, with Canada following with eight studies. 
Australia, Germany, Spain and Egypt each have one study included in the cross-walk application.  
 
For each country with data, one original data-point was chosen as the most representative POD estimate for that country, 
shown with an asterisk (*) in Table 4 below. This was the data value used for that country when mapping the prevalence 
of POD. Australia, Germany and Spain each had one study with one data-point. The data-point chosen for Canada from 
Fischer et al, 2013 was because this was the most recent data available for Canada (collected 2011), with the most 
representative age group (18 – 99 years). The data-point chosen for the US from Han et al, 2015 was also because this 
was one of the most recent data-points available (collected 2013), with the most representative age range (18 – 99 years), 
and because it had the largest sample size given its demographics. Egypt was not mapped as this was the only country 
that did not lie within the High Income Super-region. 
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Table 4: Extracted Data for Opioid Dependence, Plus Data Cross-Walked to Opioid Dependence per Super-region 
(1), Region (2) and Country / Territory (3) 
Level Location First Author 
(Year) 
Year of 
Data 
Collection 
Definition % Lower Upper 
        
1 Southeast Asia, East Asia, and Oceania 
 
nd 
  
2 East Asia 
   
nd 
  
2 Southeast Asia 
  
nd 
  
2 Oceania 
   
nd 
  
1 Central Europe, Eastern Europe, and Central Asia nd 
  
2 Central Asia 
  
nd 
  
2 Central Europe 
  
nd 
  
2 Eastern Europe 
  
nd 
  
1 High-
income 
      
2 High-income Asia Pacific 
     
2 Australasia 
     
3 Australia NDSHS 
(2013)* 
2013 An, B, M, O use: cross-
walked to dependence 
0.72% 0.58% 0.88% 
2 Western Europe 
  
0.886% 0.736% 1.066% 
3           
Germany 
Pabst 
(2013)* 
2012 NMPD dependence 3.40% 2.92% 3.95% 
3 Spain Aguilar-
Palacio 
(2014)* 
2006 An use: cross-walked to 
dependence 
4.39% 2.94% 6.51% 
2 Southern Latin America 
  
nd 
  
2 High-income North America 
     
3 Canada Currie 
(2011) 
2002 NMUPO: cross-walked to 
dependence 
0.92% 0.58% 1.47% 
3 Canada Fischer 
(2013) 
2011 NMUPO: cross-walked to 
dependence 
2.92% 2.23% 3.82% 
3 Canada Fischer 
(2013) 
2011 NMUPO: cross-walked to 
dependence 
1.11% 0.75% 1.66% 
3 Canada Shield 
(2011) 
2008-2009 NMUPO: cross-walked to 
dependence 
0.37% 0.14% 0.95% 
3 Canada Shield 
(2013b) 
2009 NMUPO: cross-walked to 
dependence 
0.90% 0.71% 1.16% 
3 Canada Fischer 
(2010) 
2008 NMUPO cross-walked to 
dependence 
0.09% 0.05% 0.18% 
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3 Canada Shield 
(2013a) 
2008-2009 NMUPO: cross-walked to 
dependence 
0.38% 0.15% 0.97% 
3 Canada Shield 
(2013a)* 
2010 NMUPO: cross-walked to 
dependence 
1.45% 0.89% 2.37% 
3 Canada Currie 
(2012) 
2008-2009 NMPD use: cross-walked to 
dependence 
0.75% 0.65% 0.87% 
3 Canada Brands 
(2010) 
2007 NMUPO: cross-walked to 
dependence 
1.17% 0.74% 1.84% 
3 US Martins 
(2010) 
2001-2002 POU disorder 0.40% 0.31% 0.51% 
3 US Fiellin 
(2013) 
2006-2008 POU: cross-walked to 
dependence 
2.22% 2.05% 2.39% 
3 US Saha (2016) 2012-2013 POU Disorder  0.89% 0.77% 1.03% 
3 US McCabe 
(2013) 
2009-2011 POU: cross-walked to 
dependence 
1.32% 0.78% 2.23% 
3 US Han (2015) 2003 POU disorder 0.60% 0.51% 0.71% 
3 US Han (2015) 2004 POU disorder 0.60% 0.51% 0.71% 
3 US Han (2015) 2005 POU disorder 0.70% 0.60% 0.82% 
3 US Han (2015) 2006 POU disorder 0.70% 0.60% 0.82% 
3 US Han (2015) 2007 POU disorder 0.80% 0.69% 0.93% 
3 US Han (2015) 2008 POU disorder 0.80% 0.69% 0.92% 
3 US Han (2015) 2009 POU disorder 0.90% 0.79% 1.03% 
3 US Han (2015) 2010 POU disorder 0.90% 0.79% 1.03% 
3 US Han (2015) 2011 POU disorder 0.80% 0.69% 0.92% 
3 US Han (2015) 2012 POU disorder 1.00% 0.88% 1.14% 
3 US Han (2015)* 2013 POU disorder 0.90% 0.78% 1.03% 
3 US Jones 
(2016) 
2006 NOU: cross-walked to 
dependence 
0.09% 0.07% 0.13% 
3 US Jones 
(2016) 
2007 NOU: cross-walked to 
dependence 
0.11% 0.08% 0.15% 
3 US Jones 
(2016) 
2008 NOU: cross-walked to 
dependence 
0.01% 0.00% 0.03% 
3 US Jones 
(2016) 
2009 NOU: cross-walked to 
dependence 
0.13% 0.10% 0.18% 
3 US Jones 
(2016) 
2010 NOU: cross-walked to 
dependence 
0.13% 0.10% 0.18% 
3 US Jones 
(2016) 
2011 NOU: cross-walked to 
dependence 
0.11% 0.08% 0.15% 
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3 US Jones 
(2016) 
2012 NOU: cross-walked to 
dependence 
0.11% 0.08% 0.15% 
3 US Jones 
(2016) 
2013 NOU: cross-walked to 
dependence 
0.09% 0.07% 0.13% 
3 US Schepis 
(2016) 
2002-2003 NMPD Use: cross-walked to 
dependence 
0.19% 0.10% 0.35% 
3 US Schepis 
(2016) 
2012-2013 Weighted NMPDU: cross-
walked to dependence 
0.32% 0.21% 0.49% 
3 US Moore 
(2009) 
2001-2002 NMUPO: cross-walked to 
dependence 
0.09% 0.04% 0.24% 
3 US Kerridge 
(2015) 
2012-2013 POU disorder 0.90% 0.78% 1.04% 
3 US Catalano 
(2011) 
2003-2004 NMUPO: cross-walked to 
dependence 
2.32% 1.28% 4.18% 
3 US Back (2010) 2006 POU disorder 1.03% 0.92% 1.15% 
3 US Boyd (2009) 2004-2005 PO dependence 0.20% 0.14% 0.28% 
3 US Biondo 
(2014) 
2005 NMUPO: cross-walked to 
dependence 
1.70% 1.44% 2.00% 
3 US Biondo 
(2014) 
2006 NMUPO: cross-walked to 
dependence 
1.70% 1.44% 2.00% 
3 US Biondo 
(2014) 
2007 NMUPO: cross-walked to 
dependence 
1.73% 1.47% 2.05% 
3 US Biondo 
(2014) 
2008 NMUPO: cross-walked to 
dependence 
1.72% 1.45% 2.02% 
3 US Biondo 
(2014) 
2009 NMUPO: cross-walked to 
dependence 
1.73% 1.47% 2.05% 
3 US Biondo 
(2014) 
2010 NMUPO: cross-walked to 
dependence 
1.64% 1.38% 1.94% 
3 US Biondo 
(2014) 
2005 NMUPO: cross-walked to 
dependence 
2.36% 1.72% 3.22% 
3 US Biondo 
(2014) 
2006 NMUPO: cross-walked to 
dependence 
2.41% 1.77% 3.29% 
3 US Biondo 
(2014) 
2007 NMUPO: cross-walked to 
dependence 
1.90% 1.34% 2.70% 
3 US Biondo 
(2014) 
2008 NMUPO: cross-walked to 
dependence 
2.41% 1.77% 3.29% 
3 US Biondo 
(2014) 
2009 NMUPO: cross-walked to 
dependence 
2.04% 1.45% 2.85% 
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3 US Biondo 
(2014) 
2010 NMUPO: cross-walked to 
dependence 
1.85% 1.29% 2.63% 
3 US Arterberry 
(2016) 
2001-2005 NMUPO: cross-walked to 
dependence 
0.30% 0.23% 0.39% 
3 US Ihongbe 
(2016) 
2011-2013 NMUPO: cross-walked to 
dependence 
1.8% 0.01663 0.01968 
1 Latin America and 
Caribbean 
  
nd 
  
2 Caribbean 
   
nd 
  
2 Andean Latin America 
  
nd 
  
2 Central Latin America 
  
nd 
  
2 Tropical Latin America 
  
nd 
  
1 North Africa and Middle 
East 
     
2 North Africa and Middle 
East 
     
3 Egypt Bassiony 
(2015)* 
2013 PO dependence 0.49% 0.05% 4.35% 
1 South Asia 
   
nd 
  
2 South Asia 
   
nd 
  
1 Sub-Saharan Africa 
  
nd 
  
2 Central Sub-Saharan Africa 
  
nd 
  
2 Eastern Sub-Saharan 
Africa 
  
nd 
  
2 Southern Sub-Saharan 
Africa 
  
nd 
  
2 Western Sub-Saharan 
Africa 
  
nd 
  
Levels: 1 = Super-region, 2 = Region, 3 = Country / Territory    
NDSHS = National Drug Strategy Household Survey    
* Data-point chosen as most representative of the population for regional population estimate    
US = United States      
nd = no data      
O = Opioids, PO = Prescription Opioids, H = Heroin, M = Methadone, B = Buprenorphine, An = Analgesics, C = Codeine  
NMUPO = Nonmedical Use of Prescription Opioids, NOU = Nonmedical Oxycontin Use, NMPD = Nonmedical Prescription 
Drug 
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3.5 Prevalence of Prescription Opioid Dependence 
Dependence data were calculated for all countries with NMUPO data. Thereafter, POD estimates (%) were calculated for 
all countries in regions and super-regions that had some data available. The countries with data on POD (original and 
imputed) were Australia, Germany, Spain, Canada and the US, all of which are in the High Income Super-region. 
Therefore, it was decided to estimate population numbers of POD only in this High Income Super-region, as it is the only 
location with an adequate amount of data. For the countries and regions within the High Income Super-region without 
data, prevalence cases were imputed based on the strategy described in detail in the Methods section.  
 
Table 5 below presents all known and imputed POD estimates per country and region. It is noted that, due to paucity of 
data, the weighted prevalences for POD were imputed for 29 out of the 34 countries in this super-region. The estimated 
number of people with POD was 2.9 million in the US, 524,000 in Canada, 215,000 in Australia, 2.8 million in Germany, and 
2.1 million in Spain. The original and imputed percentage prevalences of POD in the High Income Super-region are 
presented graphically in Figure 5 below. The overall prevalence of POD was estimated to be 2.43% (1.92 - 3.13%) in the 
High Income Super-region. Regional estimations are as follows: High Income Asia Pacific 2.43% (1.92 – 3.13%), Australasia 
0.89% (0.74 - 1.07%), Western Europe 3.77% (2.93 – 4.89%), Southern Latin America 2.43% (1.92 – 3.13%) and High 
Income North America 0.96% (0.79 – 1.17%). The only location with known data not depicted on the map is Egypt (as it is 
not part of the High Income Super-region), which has an estimated 0.5% (0.1- 4.3 95% CI) prevalence of POD. 
 
The region with the highest POD prevalence estimate is Western Europe (3.77%). Within this region, Spain has the highest 
country prevalence estimate (4.39%). The region with the lowest POD prevalence estimate is Australasia (0.89%), with 
Australia and New Zealand having an estimated 215,000 and 40,000 PO dependent people respectively. Overall, the 
country with the highest number of estimated PO dependent persons is Japan (3.1 million people) and the country with the 
lowest number is Greenland (516 people). These numbers are, of course, only estimates, and are dependent on the 
population size of the country.  
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Table 5: Estimating the Prevalence for Prescription Opioid Dependence in Countries/Territories (3) and Regions (2) of the High-Income Super-Region 
(3) Using Results from Meta-Analysis 
Level Location Population** Calculated Estimate Estimate 
% 
Lower 
95% CI 
Higher 
95% CI 
Estimated 
Number 
Low 
Number 
High 
Number 
1 HIGH-
INCOME 
1,070,090,763 Super-regional estimation, based on 
regional estimations 
2.43% 1.92% 3.13% 26,052,241 20,527,582 33,474,971 
2 High-
income Asia 
Pacific 
182,936,134 Applying super-regional estimate to region 2.43% 1.92% 3.13% 4,453,731 3,509,269 5,722,675 
3 Brunei 423,003 Applying super-regional estimate to country 2.43% 1.92% 3.13% 10,298 8,114 13,233 
3 Japan 128,306,399 Applying super-regional estimate to country 2.43% 1.92% 3.13% 3,123,725 2,461,305 4,013,728 
3 South Korea 50,283,063 Applying super-regional estimate to country 2.43% 1.92% 3.13% 1,224,183 964,581 1,572,973 
3 Singapore 3,923,668 Applying super-regional estimate to country 2.43% 1.92% 3.13% 95,525 75,268 122,742 
2 Australasia 28,884,967 Regional estimation from country with 
known data 
0.89% 0.74% 1.07% 255,895 212,698 307,771 
3 Australia* 24,321,713 Country with known data 0.89% 0.74% 1.07% 215,468 179,096 259,149 
3 New 
Zealand 
4,563,255 Applying regional estimate to country 0.89% 0.74% 1.07% 40,426 33,602 48,622 
2 Western 
Europe 
433,621,186 Regional estimation from country with 
known data 
3.77% 2.93% 4.89% 16,326,994 12,703,241 21,219,276 
3 Andorra 79,452 Applying regional estimate to country 3.77% 2.93% 4.89% 2,992 2,328 3,888 
3 Austria 8,669,942 Applying regional estimate to country 3.77% 2.93% 4.89% 326,446 253,992 424,264 
3 Belgium 11,332,642 Applying regional estimate to country 3.77% 2.93% 4.89% 426,704 331,998 554,563 
3 Cyprus 891,960 Applying regional estimate to country 3.77% 2.93% 4.89% 33,585 26,131 43,648 
3 Denmark 5,710,725 Applying regional estimate to country 3.77% 2.93% 4.89% 215,024 167,300 279,455 
3 Finland 5,550,457 Applying regional estimate to country 3.77% 2.93% 4.89% 208,989 162,605 271,612 
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3 France 65,232,014 Applying regional estimate to country 3.77% 2.93% 4.89% 2,456,159 1,911,018 3,192,132 
3 Germany* 83,628,107 Country with known data 3.40% 2.92% 3.95% 2,843,356 2,443,455 3,306,039 
3 Greece 10,921,532 Applying regional estimate to country 3.77% 2.93% 4.89% 411,225 319,954 534,446 
3 Iceland 326,395 Applying regional estimate to country 3.77% 2.93% 4.89% 12,290 9,562 15,972 
3 Ireland 4,789,767 Applying regional estimate to country 3.77% 2.93% 4.89% 180,348 140,320 234,388 
3 Israel 8,049,386 Applying regional estimate to country 3.77% 2.93% 4.89% 303,081 235,812 393,897 
3 Italy 62,797,397 Applying regional estimate to country 3.77% 2.93% 4.89% 2,364,489 1,839,694 3,072,994 
3 Luxembourg 556,434 Applying regional estimate to country 3.77% 2.93% 4.89% 20,951 16,301 27,229 
3 Malta 418,373 Applying regional estimate to country 3.77% 2.93% 4.89% 15,753 12,257 20,473 
3 Netherlands 17,190,587 Applying regional estimate to country 3.77% 2.93% 4.89% 647,271 503,610 841,222 
3 Norway 5,164,354 Applying regional estimate to country 3.77% 2.93% 4.89% 194,452 151,293 252,718 
3 Portugal 10,799,730 Applying regional estimate to country 3.77% 2.93% 4.89% 406,639 316,386 528,485 
3 Spain* 48,751,005 Country with known data 4.39% 2.94% 6.51% 2,141,071 1,434,685 3,171,940 
3 Sweden 9,807,976 Applying regional estimate to country 3.77% 2.93% 4.89% 369,296 287,332 479,954 
3 Switzerland 8,278,353 Applying regional estimate to country 3.77% 2.93% 4.89% 311,702 242,520 405,102 
3 United 
Kingdom 
64,243,837 Applying regional estimate to country 3.77% 2.93% 4.89% 2,418,952 1,882,069 3,143,776 
2 Southern 
Latin 
America 
64,798,432 Applying super-regional estimate to region 2.43% 1.92% 3.13% 1,577,571 1,243,030 2,027,048 
3 Argentina 43,413,241 Applying super-regional estimate to country 2.43% 1.92% 3.13% 1,056,931 832,797 1,358,069 
3 Chile 17,948,052 Applying super-regional estimate to country 2.43% 1.92% 3.13% 436,960 344,298 561,458 
3 Uruguay 3,434,236 Applying super-regional estimate to country 2.43% 1.92% 3.13% 83,609 65,879 107,431 
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2 High-
income 
North 
America 
359,850,051 Regional estimation from country with 
known data 
0.96% 0.79% 1.17% 3,438,050 2,859,344 4,198,201 
3 Canada* 36,145,518 Country with known data 1.45% 0.89% 2.37% 524,610 320,629 855,263 
3 Greenland 54,024 Applying regional estimate to country 0.96% 0.79% 1.17% 516 429 630 
3 United 
States* 
323,526,036 Country with known data 0.90% 0.78% 1.03% 2,911,734 2,537,296 3,340,855 
*country with original data; locations with no data where estimates were imputed based on other locations within the regions are italicized  
** Population size ages 15-64 years from: Global Burden of Disease Study 2015. Global Burden of Disease Study 2015 (GBD 2015) Population Estimates 1970-
2015. Seattle, United States: Institute for Health Metrics and Evaluation (IHME), 2016. 
CI = Confidence Interval 
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As can clearly be seen in Figure 5 below, there are very few places on the global map for which data is available, whether 
original or estimated. It is noted that only two locations – the US and Germany – have original POD data available (i.e. data 
not calculated from cross-walk) in the High Income Super-region (representing 34 countries / territories). The only other 
original POD data available is from Egypt in the North Africa and Middle East Super-region (which comprises 21 countries 
/ territories). Super-regions with no data found through this systematic review include Southeast Asia, East Asia and 
Oceania (28 countries / territories); Central Europe, Eastern Europe and Central Asia (29 countries / territories); Latin 
America and Caribbean (32 countries / territories); South Asia (5 countries / territories); and Sub-Saharan Africa (46 
countries / territories).  This highlights the huge gap that currently exists within the database for PO NMU and dependence.  
 
 
 
Figure 5: Map of High-Income Super-Region Estimated Prevalence of Prescription Opioid Dependence Using 
Cross-Walked Data
Estimated Prevalence of Prescript ion Opioid Dependence in the High-Income Super-Region
0.000 4.000
%
Map based on Longit ude (generat ed) and Lat it ude (generat ed).  Color  shows det ails about  %.  Det ails are shown for  Count ry.
Estimated Prevalence of Prescript ion Opioid Dependence in the High-Income Super-Region
0.000 4.000
%
Map based on Longit ude (generat ed) and Lat it ude (generat ed).  Color  shows det ails about  %.  Det ails are shown for  Count ry.
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4. DISCUSSION 
The increasing trends of NMUPO prevalence has become a concern, and mapping the global prevalence 
of POD has become imperative to quantify the burden of disease due to POs, as well as to better inform 
prevention and treatment programs. This study systematically reviewed all recent peer-reviewed literature 
on the prevalence of NMUPO and POD. 
 
The highest prevalence of POD prior to further adjustments and estimation of data is 3.4% in Germany. 
This is higher than the results of the GBD 2015 study (which focused on heroin) results (34), and showed 
prevalence estimates of 0.38% (0.34-0.43%). This highlights how easily important data can be missed if 
studies continue to examine prevalence data for heroin only, without taking into consideration PO data. 
 
Cross-walk meta-analysis using data from studies with POD and NMUPO prevalence gave a pooled RR of 
0.19. This ratio was used to adjust the prevalence of available NMUPO data towards the POD prevalence 
in the High Income Super-region, which had the most data available for analysis. It is thought that an 
estimated POD prevalence is more valuable than having no data for POD prevalence at all. After application 
of the cross-walk RR, results on weighted prevalence within the High Income Super-regions show that the 
region with the highest estimated POD prevalence was Western Europe (3.77%, 2.93-4.89%), while the 
region with the lowest estimate was Australasia (0.89%, 0.74-1.07%). This higher estimated prevalence 
was driven by the high NMUPO and POD prevalence data from Germany and Spain. This result is 
surprising, as it was expected that the region with the highest prevalence would be High Income North 
America, as the US lies within this region (see Figure 6). The overall super-regional estimate of prevalence 
of POD for the High Income Super-region was 2.43% (1.92 – 3.13%). The GBD 2015 results on the 
prevalence of opioid dependence in the High Income Super-region was 0.38% (0.34-0.43%), which 
potentially suggests that the burden of opioid dependence estimated without considering POs may be an 
underestimate. 
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Figure 6 Prevalence of Opioid Use Disorders from the Global Burden of Disease 2015 Findings 
(figure from GBD Compare online) (35) 
 
The GBD study looks at substance dependence globally, with a focus on cannabis, opioids, cocaine and 
amphetamines. However, the GBD study does not differentiate between prescription and illicit opioids, and 
therefore does not do a separate analysis on POD or NMUPOs. The current GBD 2015 study focuses 
predominantly on heroin (36), as this is traditionally where the highest disease burden lies.  The GBD study 
also uses data that originates mainly in high-income countries, due to the availability and accessibility of 
data sources, with a minimal number of studies from other countries, as there has been a paucity of data 
from other parts of the world (37). The World Mental Health Survey (WMHS), undertaken by the World 
Health Organization (WHO), is considered the Gold Standard mental health resource globally (38). 
However, the WMHS only describes the overall prevalence of substance dependence and includes all the 
substances together. The WMHS does not examine opioids – illicit or prescription – as a separate entity.  
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Therefore, and as far as the author is aware, this is the first global systematic review and meta-analysis of 
NMUPO and POD conducted, and as such is an important contribution to the current body of literature. 
This study gives an overview of the available literature and data on prescription opioid nonmedical use and 
dependence globally, and highlights the significant gaps that currently exist within the literature.  
 
4.1 United States Data  
Most data-points are from the US (61 out of 114), and the overwhelming majority of data-points in the 
cross-walk to dependence are also from the US (44 out of 58) (Table 3 and Table 4). Despite not having 
the highest POD prevalence extrapolated within this project, POD and mortality have been increasing 
markedly in the US, even when compared to countries of a similar economic level (4). The US has a 
different demographic and social profile to other regions of the world, with regards to its affluence, political 
structure and health structure. A major difference is the ability of pharmaceutical companies to legally 
market their products directly to the general consumer (4), thereby creating a demand for a particular 
product as portrayed by advertising (regardless of its medical indication), drug interactions or risks. The 
prescription of POs has been shown to increase consumer satisfaction with physicians in the US (4). 
 
In the past, physicians have been encouraged to prescribe opioid medication for pain, and this trend has 
continued in the US despite current misgivings regarding its efficacy in chronic, non-cancer pain (4, 39). 
Some physicians have even been known to prescribe POs without interviewing the patient, contributing to 
schemes known as “pill mills” (4).  Even methadone, usually reserved for observed OST for opioid 
dependence in other countries, is increasingly prescribed as pain relief in the US, despite knowledge that 
side effects are greater and risk of overdose higher with methadone compared to other POs, such as 
oxycodone or tramadol (4). Another poor prescribing practice evidenced in the US is the concurrent 
prescription of opioids and benzodiazepines (BZDs), a sedative and anxiolytic class of medications. BZDs 
are thought to increase the dependent component of opioids through various neuro-mechanisms, and 
trends of both classes of medications are on the rise in the US (4).  
 
One of the factors affecting the increasing trends of NMUPO in the US may be the reportedly high price of 
heroin in the US compared to POs (4); for example, $450/g in the US, and $62/g in the UK, as reported in 
the World Drug Report 2012 (in Weisberg et al, 2014). The relative price of, and access to, heroin and POs 
have been shown to affect the preference of the user, and these drugs have been shown to “share a market” 
(4).  These drugs also share a high level of morbidity and mortality, and NMUPO should be as closely 
monitored as heroin use, as it can be just as unsafe taken illicitly. 
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4.2 Heroin Use 
There were four studies accepted and only five data-points extracted on heroin use and dependence after 
the screening process. Most studies screened focused on heroin users or treatment groups, and were 
therefore excluded from this analysis. Heroin use prevalence among 16-18 year olds in Thailand was 1.52% 
(Wongtongkam et al 2015) (40), and 0.73% among 18-25 year olds in the US (Ihongbe and Masho, 2016) 
(6). Heroin dependence prevalence was 0.21% among 15-65 year olds in the Czech Republic (Sopko et al, 
2016) (41). Data from the EMCDDA showed <0.01% prevalence of heroin dependence in both Italy and 
Spain. The low prevalence of heroin dependence in Spain is surprising given the high prevalence of 
NMUPO given in the Aguilar-Palacio et al (2014) (42) study (23.3%) and the resulting high, imputed POD 
prevalence estimate in Spain (4.39%).  
 
In the US, heroin dependence among 18-25 year olds had a much lower prevalence compared to other 
opioids (like codeine) in a similar age group (0.73% compared to 9.6%). This is most likely due to reduced 
access to illicit drugs compared to over-the-counter opioids, as well as the perceived higher safety of over-
the-counter opioids compared to heroin. However, these age demographics are not representative of the 
general population. There have been reports of problem heroin use in Asia (43), particularly in China, 
Pakistan, Iran and India (14), but results from this project found no data available on POD for these 
countries. Further data is required to examine if NMUPOs and POD is a concern in locations outside of 
high-income regions. 
 
4.3 Age and Sex Demographics 
School-based studies appear to have a higher prevalence of NMUPO, and this signifies that adolescents 
and young adults are more at risk of NMUPO. This could be due to an increased desire and willingness to 
experiment in this age group, or could be an indicator of increasing stress in today’s younger population. 
However, this could also be partially attributed to unreliability of self-report in this age group. All school-
based studies extracted for this project showed only NMUPOs and not POD (Fischer et al, 2013, Currie 
and Wild, 2012, Brands et al, 2010, McCabe et al, 2013, Catalano et al 2011, Biondo and Chilcoat, 2014), 
with one exception (Bassiony et al, 2015). The cross-walk ratio calculated for the adjustment of NMUPO 
prevalence to POD prevalence may not be applicable to a school-age sample, however, and further studies 
employing a cross-walk analysis to impute POD prevalence data should consider a separate cross-walk 
analysis for school-based data.  
 
In the Egyptian study containing both NMUPO and POD prevalence data (Bassiony et al, 2015), 18 students 
out of 204 sampled in this study used POs non-medically, while one student was PO dependent (44). 
Dependence was identified using the Drug Use Disorders Identification Test (based on the Alcohol Use 
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Disorders Identification Test by the WHO). It is suggested that further studies examining NMUPO and POD 
use standardised assessment tools, as well as DSM or ICD criteria, to identify PO NMU and dependence 
in school-based samples. This provides a more reliable evidence base to identify those students most at 
risk, and to assist in the appropriate development of more intense and tailored interventions for this age 
demographic. 
 
On the other end of the spectrum, and with the increase in opioid prescribing trends, the older age groups 
(who are more prone to chronic, painful medical conditions such as osteoarthritis or back pain) are also at 
risk of PO NMU and dependence. As this age group (50+ years) increases in numbers due to longer life 
expectancies in many countries, the amounts of POs prescribed to this demographic, and all the problems 
associated with this, will also increase. This is something clinicians must be aware of and take into 
consideration when prescribing pain treatments. It may be of benefit for physicians to be educated on other 
pain management methods, and for the health system to adequately compensate health practitioners when 
prescribing non-opioid treatments, to encourage more beneficial management plans, which may also be 
more time-consuming. 
 
There were a total of four studies in this analysis that presented data stratified by sex on POD, and only 
two of those studies had valid data on both NMUPO and POD. Currently, the demographic with the highest 
burden due to opioid use disorder is young males (12), as this is the group with the highest prevalence of 
heroin dependence. However, this may change if POD continues to increase, and other age groups and 
female sex increase in prevalence.  Due to the lack of data, analyses according to sex were not possible in 
this project. However, it would be useful to analyse results stratified by sex in future studies when more 
results become available, as results may differ significantly according to sex. This will contribute to our 
understanding of the disease burden due to POs, and help target prevention and intervention strategies. 
 
4.4 Limitations  
There were a number of limitations to this study, and it is advisable, therefore, to interpret and use these 
study results with due consideration. There were only four studies, and four data points used, to perform 
the cross-walk analysis to obtain the RR of 0.19 in this study. All studies in this cross-walk were from the 
US, and one study was from 2002. Given the above, this RR is US specific, but as it uses all the data 
available from this project, this is the RR used to impute estimated prevalences for POD in all countries 
with available NMUPO data and no POD data. 
 
Estimated weighted prevalences of POD were imputed for the High Income Super-region, leaving much of 
the world unaccounted for. Even in this super-region however, the overwhelming majority of the data (29 
countries out of 34) were imputed. Only five countries had data from original studies available for use, as 
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identified in this project, and not all of the data had age ranges representative of the general population, 
with some studies having younger age ranges (eg. Brands et al, 2010: age 12-19 years old). 
 
As well as this, and even though of some benefit compared to no data, it must be remembered that most 
of the POD prevalence estimates in this paper are extrapolated from NMU data, and actual POD prevalence 
may be higher or lower. However, a standardized method to make adjustments was used, and standard 
errors from original data and the cross-walk ratios were incorporated into the adjustments, which form a 
standardized basis for PO prevalence estimates based on the current available data. Future studies that 
collect data on POD can help assess the validity of these findings, and provide better data to inform the 
cross-walk ratio and further adjustments. 
 
During the development of the study design, it was planned to analyse the data according to sex, to enable 
a comparison of males to females globally. This was not possible, however, as there was a paucity of data 
available (only two studies) with both NMUPO and POD that stratified data according to sex. It was also 
planned to map POD for all super-regions and regions globally, but this was also not possible due to the 
lack of data.  
 
There may be data for other regions and super-regions available in other languages in local journals (e.g. 
Spanish and Portuguese articles for the Latin America and Caribbean Super-region), or within the grey 
literature, but, although we did not exclude non-English articles, due to English search strings, these studies 
may not have been picked up in this systematic review. This paucity of data on POs has previously been 
documented by other studies, however. A systematic review by Degenhardt et al (2011) revealed studies 
from 25 countries pertaining to opioid dependence. All studies, however, focused on heroin or illicit opioids 
(45).  
 
4.5 Future Areas of Research 
The paucity of data globally has been highlighted in this paper, particularly in regions that are less 
economically affluent. General population surveys – local or national – can be costly, time-consuming and 
resource intensive, and it may be understandable that authorities use precious resources elsewhere.  
Therefore, an alternative approach to population-based surveys suggested  is analysis of wastewater. This 
method is gaining recognition internationally, and is quick, cost-effective and not as human resource 
intensive (46-50). Wastewater analysis uses the measurement of target drug excretion residues, or 
metabolites, found in sewage wastewater (47), and has been shown to give similar, comparative results to 
population surveys (51). It gives a timely snapshot of relevant metabolites and can elicit daily, weekly, 
fortnightly etc changes in opioid use (49). The disadvantage of this method is that, while it can provide data 
on the overall amount of drugs used by the community, this method does not provide data on the number 
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of users. In addition, PO and illicit opioids cannot yet be distinguished, as the target metabolites measured 
are the same. However, there are slightly different pathways of metabolism, and if this area of research is 
seriously considered, it may be possible to find different, measurable target metabolites to differentiate 
between illicit and POs. While not as effective as population-based surveys, wastewater analysis has the 
potential to analyse the overall amounts and types of drugs used within the community, particularly in lower 
resourced areas. 
 
4.6 Conclusion 
 
This study has found prevalence of POD up to 3.4% in some countries, with the highest estimated POD 
prevalence data in the Western European region. This result was unexpected, and highlights the need for 
further research to elicit the actual prevalence and burden of POD globally. The increasing trends of 
NMUPO and POD prevalence are of increasing concern. However, the prevalence of POD is not able to 
be mapped globally given the current lack of data in many regions of the world. Some evidence exists that 
POD poses a large burden on the community, even overtaking the burden of heroin use in some places, 
but this is not yet able to be validated. A quantification of the epidemiology and disease burden of POs 
enables the timely and efficacious implementation of cost-effective prevention and intervention strategies, 
and this may be able to save much morbidity and mortality globally. 
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6. APPENDICES 
6.1 Appendix 6.1: Database Search Strategy and Strings 
Search Terms for Global Burden of Disease 2016 
Epidemiology of opioids, cocaine, amphetamine, and cannabis use or dependence 
 
Search strategy 
Search ((1 & 2) OR 3 ) & 4 
 
Group 1: substance (everything within this group OR) 
 
adderall (within title and abstract) 
Amphetamin* (within title and abstract) 
analges* (within title and abstract) 
Cannabis (within title and abstract) 
Cocaine (within title and abstract) 
codeine (within title and abstract) 
Crack (within title and abstract) 
Hashish (within title and abstract) 
heroin (within title and abstract) 
“illicit drug” (within title and abstract) 
“illicit substance” (within title and abstract) 
Marijuana (within title and abstract) 
Methamphetam* (within title and abstract)  
narcotic* (within title and abstract) 
opiate* (within title and abstract) 
opioid* (within title and abstract) 
oxycodone (within title and abstract) 
oxycotin (within title and abstract) 
pain-reli* (within title and abstract) 
“pain relief” (within title and abstract) 
“pain reliever” (within title and abstract) 
“prescription drug” (within title and abstract) 
“prescription substance” (within title and abstract) 
ritalin (within title and abstract)  
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Shabu (within title and abstract) 
Stimulant* (within title and abstract) 
Substance (within title and abstract) 
vicodin (within title and abstract)  
Yaba (within title and abstract) 
 
Group 2: use or dependence (everything within this group OR) 
abus* (within title and abstract) 
addict* (within title and abstract) 
consum* (within title and abstract) 
dependen* (within title and abstract) 
misus* (within title and abstract) 
non-medic* (within title and abstract) 
smok* (within title and abstract) 
use (within title and abstract) 
 
Dependency (psychology) (MeSH term) 
 
Group 3: substance use or substance dependence Mesh terms (everything within this group OR) 
 
“cannabis addiction” (Emtree term) 
“cannabis smoking” (Emtree term) 
“cannabis use” (Emtree term) 
“cocaine dependence” (Emtree term) 
“Drug abuse pattern” (Emtree term) 
“Drug abuse” (Emtree term) 
“Drug dependence” (Emtree term) 
“Drug misuse” (Emtree term) 
“Drug use” (Emtree term) 
“heroin dependence” (Emtree term) 
“methamphetamine dependence” (Emtree term) 
“narcotic dependence” (Emtree term) 
“Substance abuse” (Emtree term) 
 
“Drug users” (MeSH term) 
“Heroin dependence” (MeSH term) 
“Marijuana abuse” (MeSH term) 
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“Marijuana smoking” (MeSH term) 
“Morphine dependence” (MeSH term) 
“Prescription drug diversion” (MeSH term) 
“Prescription drug misuse” (MeSH term) 
“Prescription drug overuse” (MeSH term) 
“Substance-related disorders” (MeSH term) 
 
“Drug abuse” (PsycINFO term) 
“Drug addiction” (PsycINFO term) 
“Drug dependence” (PsycINFO term) 
“Drug dependency” (PsycINFO term) 
“Drug usage” (PsycINFO term) 
“Heroin addiction” (PsycINFO term) 
“Marijuana usage” (PsycINFO term) 
“Substance abuse and addiction measures” (PsycINFO term) 
“Substance use disorder” (PsycINFO term) 
 
Group 4: Parameter-specific search terms (everything within this group OR) 
death* (within title and abstract) 
duration (within title and abstract) 
epidemiolog* (within title and abstract) 
inciden* (within title and abstract) 
mortality* (within title and abstract) 
prevalen* (within title and abstract) 
recurren* (within title and abstract) 
remission (within title and abstract) 
remit* (within title and abstract) 
 
Cohort studies (MeSH term) 
Cross-sectional studies (MeSH term) 
Epidemiology (Mesh term) 
Incidence (Mesh term) 
Mortality (Mesh term) 
Prevalence (Mesh term) 
Recurrence (Mesh term) 
 
Incidence (Emtree term) 
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Morbidity (Emtree term) 
Mortality rate (Emtree term) 
Prevalence (Emtree term) 
Recurrence risk (Emtree term) 
Recurrent disease (Emtree term) 
Remission (Emtree term) 
 
Mortality rate (PsycINFO term) 
Relapse (Disorders) (PsycINFO term) 
Remission (Disorders) (PsycINFO term) 
 
  
Psycinfo search via EBSCOhost, conducted date 2016.09.16 
 
 (((TI adderall OR AB adderall OR TI Amphetamin* OR AB Amphetamin* OR TI analges* OR AB analges* 
OR TI Cannabis OR AB Cannabis OR TI Cocaine OR AB Cocaine OR TI codeine OR AB codeine OR TI 
Crack OR AB Crack OR TI Hashish OR AB Hashish OR TI heroin OR AB heroin OR TI “illicit drug” OR AB 
“illicit drug” OR TI “illicit substance” OR AB “illicit substance” OR TI Marijuana OR AB Marijuana OR TI 
Methamphetam* OR AB Methamphetam* OR TI narcotic* OR AB narcotic* OR TI opiate* OR AB opiate* 
OR TI opioid* OR AB opioid* OR TI oxycodone OR AB oxycodone OR TI oxycotin OR AB oxycotin OR TI 
pain-reli* OR AB pain-reli* OR TI “pain relief” OR AB “pain relief” OR TI “pain reliever” OR AB “pain reliever” 
OR TI “prescription drug” OR AB “prescription drug” OR TI “prescription substance” OR AB “prescription 
substance” OR TI ritalin OR AB ritalin OR TI Shabu OR AB Shabu OR TI Stimulant* OR AB Stimulant* OR 
TI Substance OR AB Substance OR TI vicodin OR AB vicodin OR TI Yaba OR AB Yaba) AND (TI abus* 
OR AB abus* OR TI addict* OR AB addict* OR TI consum* OR AB consum* OR TI dependen* OR AB 
dependen* OR TI misus* OR AB misus* OR TI non-medic* OR AB non-medic* OR TI smok* OR AB smok* 
OR TI use OR AB use OR MA Dependency)) OR (MA “Drug users” OR MA “Heroin dependence” OR MA 
“Marijuana abuse” OR MA “Marijuana smoking” OR MA “Morphine dependence” OR MA “Prescription drug 
diversion” OR MA “Prescription drug misuse” OR MA “Prescription drug overuse” OR MA “Substance-
related disorders” OR KW “Drug abuse” OR KW “Drug addiction” OR KW “Drug dependence” OR KW “Drug 
dependency” OR KW “Drug usage” OR KW “Heroin addiction” OR KW “Marijuana usage” OR KW 
“Substance abuse and addiction measures” OR KW “Substance use disorder)) AND (TI prevalen* OR AB 
prevalen* OR TI mortality* OR AB mortality* OR TI death* OR AB death* OR TI inciden* OR AB inciden* 
OR TI recurren* OR AB recurren* OR TI remission OR AB remission OR TI duration OR AB duration OR 
TI remit* OR AB remit* OR TI epidemiolog* OR AB epidemiolog* OR KW Mortality rate OR KW Relapse 
OR KW Remission OR MA Cohort studies OR MA Cross-sectional studies OR MA Epidemiology OR MA 
Incidence OR MA Mortality OR MA Prevalence OR MA Recurrence) 
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Limiters - Publication Year: 2009-; Publication Type: Peer Reviewed Journal; Population Group: Human 
Search modes - Boolean/Phrase 
 
Result  
12180 
 
Medline search via EBSCOhost, conducted date 2016.09.16 
 
 (((TI adderall OR AB adderall OR TI Amphetamin* OR AB Amphetamin* OR TI analges* OR AB analges* 
OR TI Cannabis OR AB Cannabis OR TI Cocaine OR AB Cocaine OR TI codeine OR AB codeine OR TI 
Crack OR AB Crack OR TI Hashish OR AB Hashish OR TI heroin OR AB heroin OR TI “illicit drug” OR AB 
“illicit drug” OR TI “illicit substance” OR AB “illicit substance” OR TI Marijuana OR AB Marijuana OR TI 
Methamphetam* OR AB Methamphetam* OR TI narcotic* OR AB narcotic* OR TI opiate* OR AB opiate* 
OR TI opioid* OR AB opioid* OR TI oxycodone OR AB oxycodone OR TI oxycotin OR AB oxycotin OR TI 
pain-reli* OR AB pain-reli* OR TI “pain relief” OR AB “pain relief” OR TI “pain reliever” OR AB “pain reliever” 
OR TI “prescription drug” OR AB “prescription drug” OR TI “prescription substance” OR AB “prescription 
substance” OR TI ritalin OR AB ritalin OR TI Shabu OR AB Shabu OR TI Stimulant* OR AB Stimulant* OR 
TI Substance OR AB Substance OR TI vicodin OR AB vicodin OR TI Yaba OR AB Yaba) AND (TI abus* 
OR AB abus* OR TI addict* OR AB addict* OR TI consum* OR AB consum* OR TI dependen* OR AB 
dependen* OR TI misus* OR AB misus* OR TI non-medic* OR AB non-medic* OR TI smok* OR AB smok* 
OR TI use OR AB use OR MM Dependency OR MH Dependency)) OR (MH “Drug users” OR MH “Heroin 
dependence” OR MH “Marijuana abuse” OR MH “Marijuana smoking” OR MH “Morphine dependence” OR 
MH “Prescription drug diversion” OR MH “Prescription drug misuse” OR MH “Prescription drug overuse” 
OR MH “Substance-related disorders” OR MM “Drug users” OR MM “Heroin dependence” OR MM 
“Marijuana abuse” OR MM “Marijuana smoking” OR MM “Morphine dependence” OR MM “Prescription 
drug diversion” OR MM “Prescription drug misuse” OR MM “Prescription drug overuse” OR MM “Substance-
related disorders” OR KW “Drug abuse” OR KW “Drug addiction” OR KW “Drug dependence” OR KW “Drug 
dependency” OR KW “Drug usage” OR KW “Heroin addiction” OR KW “Marijuana usage” OR KW 
“Substance abuse and addiction measures” OR KW “Substance use disorder)) AND (TI prevalen* OR AB 
prevalen* OR TI mortality* OR AB mortality* OR TI death* OR AB death* OR TI inciden* OR AB inciden* 
OR TI recurren* OR AB recurren* OR TI remission OR AB remission OR TI duration OR AB duration OR 
TI remit* OR AB remit* OR TI epidemiolog* OR AB epidemiolog* OR KW Mortality rate OR KW Relapse 
OR KW Remission OR MH Cohort studies OR MH Cross-sectional studies OR MH Epidemiology OR MH 
Incidence OR MH Mortality OR MH Prevalence OR MH Recurrence OR MM Cohort studies OR MM Cross-
sectional studies OR MM Epidemiology OR MM Incidence OR MM Mortality OR MM Prevalence OR MM 
Recurrence) 
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Limiters - Date of Publication: 20090101-; Human; Journal & Citation Subset: MEDLINE, Pubmed Central; 
Publication Type: Journal Article 
Search modes - Boolean/Phrase 
 
Results 
18930 
 
 
Embase search, conducted date 2016.09.16 
 
adderall:ab,ti OR amphetamin*:ab,ti OR analges*:ab,ti OR cannabis:ab,ti OR cocaine:ab,ti OR 
codeine:ab,ti OR crack:ab,ti OR hashish:ab,ti OR heroin:ab,ti OR 'illicit drug':ab,ti OR 'illicit substance':ab,ti 
OR marijuana:ab,ti OR methamphetam*:ab,ti OR narcotic*:ab,ti OR opiate*:ab,ti OR opioid*:ab,ti OR 
oxycodone:ab,ti OR oxycotin:ab,ti OR 'pain reli*':ab,ti OR 'pain relief':ab,ti OR 'pain reliever':ab,ti OR 
'prescription drug':ab,ti OR 'prescription substance':ab,ti OR ritalin:ab,ti OR shabu:ab,ti OR stimulant*:ab,ti 
OR substance:ab,ti OR vicodin:ab,ti OR yaba:ab,ti AND (abus*:ab,ti OR addict*:ab,ti OR consum*:ab,ti OR 
dependen*:ab,ti OR misus*:ab,ti OR 'non medic*':ab,ti OR smok*:ab,ti OR use:ab,ti) OR 'cannabis 
addiction'/exp OR 'cannabis smoking'/exp OR 'cannabis use'/exp OR 'cocaine dependence'/exp OR 'drug 
abuse pattern'/exp OR 'drug abuse'/exp OR 'drug dependence'/exp OR 'drug misuse'/exp OR 'drug use'/exp 
OR 'heroin dependence'/exp OR 'methamphetamine dependence'/exp OR 'narcotic dependence'/exp OR 
'substance abuse'/exp AND (death*:ab,ti OR duration:ab,ti OR epidemiolog*:ab,ti OR inciden*:ab,ti OR 
mortality:ab,ti OR prevalen*:ab,ti OR recurren*:ab,ti OR remission:ab,ti OR remit:ti OR incidence:ab,ti OR 
morbidity:ab,ti OR 'mortality rate'/exp OR 'prevalence'/exp OR 'recurrence risk'/exp OR 'recurrent 
disease'/exp OR 'remission'/exp) AND ([article]/lim OR [article in press]/lim) AND [humans]/lim AND 
[english]/lim AND [embase]/lim AND [2009-2016]/py 
 
Results 
30266 
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6.2 Appendix 6.2: World Regions 
Table 6: Location Level and Identification of Super-Regions (1), Regions (2) and 
Countries/Territories (3) 
 
LEVEL LOCATION NAME 
1 SOUTHEAST ASIA, EAST ASIA, AND OCEANIA 
2 East Asia 
3 China 
3 North Korea 
3 Taiwan 
2 Southeast Asia 
3 Cambodia 
3 Indonesia 
3 Laos 
3 Malaysia 
3 Maldives 
3 Mauritius 
3 Myanmar 
3 Philippines 
3 Sri Lanka 
3 Seychelles 
3 Thailand 
3 Timor-Leste 
3 Vietnam 
2 Oceania 
3 American Samoa 
3 Federated States of Micronesia 
3 Fiji 
3 Guam 
3 Kiribati 
3 Marshall Islands 
3 Northern Mariana Islands 
3 Papua New Guinea 
3 Samoa 
3 Solomon Islands 
3 Tonga 
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3 Vanuatu 
1 CENTRAL EUROPE, EASTERN EUROPE, AND CENTRAL ASIA 
2 Central Asia 
3 Armenia 
3 Azerbaijan 
3 Georgia 
3 Kazakhstan 
3 Kyrgyzstan 
3 Mongolia 
3 Tajikistan 
3 Turkmenistan 
3 Uzbekistan 
2 Central Europe 
3 Albania 
3 Bosnia and Herzegovina 
3 Bulgaria 
3 Croatia 
3 Czech Republic 
3 Hungary 
3 Macedonia 
3 Montenegro 
3 Poland 
3 Romania 
3 Serbia 
3 Slovakia 
3 Slovenia 
2 Eastern Europe 
3 Belarus 
3 Estonia 
3 Latvia 
3 Lithuania 
3 Moldova 
3 Russia 
3 Ukraine 
1 HIGH-INCOME 
2 High-income Asia Pacific 
3 Brunei 
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3 Japan 
3 South Korea 
3 Singapore 
2 Australasia 
3 Australia 
3 New Zealand 
2 Western Europe 
3 Andorra 
3 Austria 
3 Belgium 
3 Cyprus 
3 Denmark 
3 Finland 
3 France 
3 Germany 
3 Greece 
3 Ireland 
3 Israel 
3 Italy 
3 Luxembourg 
3 Malta 
3 Netherlands 
3 Norway 
3 Portugal 
3 Spain 
3 Sweden 
3 Switzerland 
3 United Kingdom 
2 Southern Latin America 
3 Argentina 
3 Chile 
3 Uruguay 
2 High-income North America 
3 Canada 
3 Greenland 
3 United States 
1 LATIN AMERICA AND CARIBBEAN 
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2 Caribbean 
3 Antigua and Barbuda 
3 The Bahamas 
3 Barbados 
3 Belize 
3 Bermuda 
3 Cuba 
3 Dominica 
3 Dominican Republic 
3 Grenada 
3 Guyana 
3 Haiti 
3 Jamaica 
3 Puerto Rico 
3 Saint Lucia 
3 Saint Vincent and the Grenadines 
3 Suriname 
3 Trinidad and Tobago 
3 Virgin Islands, U.S. 
2 Andean Latin America 
3 Bolivia 
3 Ecuador 
3 Peru 
2 Central Latin America 
3 Colombia 
3 Costa Rica 
3 El Salvador 
3 Guatemala 
3 Honduras 
3 Mexico 
3 Nicaragua 
3 Panama 
3 Venezuela 
2 Tropical Latin America 
3 Brazil 
3 Paraguay 
1 NORTH AFRICA AND MIDDLE EAST 
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2 North Africa and Middle East 
3 Afghanistan 
3 Algeria 
3 Bahrain 
3 Egypt 
3 Iran 
3 Iraq 
3 Jordan 
3 Kuwait 
3 Lebanon 
3 Libya 
3 Morocco 
3 Palestine 
3 Oman 
3 Qatar 
3 Saudi Arabia 
3 Sudan 
3 Syria 
3 Tunisia 
3 Turkey 
3 United Arab Emirates 
3 Yemen 
1 SOUTH ASIA 
2 South Asia 
3 Bangladesh 
3 Bhutan 
3 India 
3 Nepal 
3 Pakistan 
1 SUB-SAHARAN AFRICA 
2 Central Sub-Saharan Africa 
3 Angola 
3 Central African Republic 
3 Congo 
3 Democratic Republic of the Congo 
3 Equatorial Guinea 
3 Gabon 
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2 Eastern Sub-Saharan Africa 
3 Burundi 
3 Comoros 
3 Djibouti 
3 Eritrea 
3 Ethiopia 
3 Kenya 
3 Madagascar 
3 Malawi 
3 Mozambique 
3 Rwanda 
3 Somalia 
3 South Sudan 
3 Tanzania 
3 Uganda 
3 Zambia 
2 Southern Sub-Saharan Africa 
3 Botswana 
3 Lesotho 
3 Namibia 
3 South Africa 
3 Swaziland 
3 Zimbabwe 
2 Western Sub-Saharan Africa 
3 Benin 
3 Burkina Faso 
3 Cameroon 
3 Cape Verde 
3 Chad 
3 Cote d'Ivoire 
3 The Gambia 
3 Ghana 
3 Guinea 
3 Guinea-Bissau 
3 Liberia 
3 Mali 
3 Mauritania 
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3 Niger 
3 Nigeria 
3 Sao Tome and Principe 
3 Senegal 
3 Sierra Leone 
3 Togo 
1 = Super-region 
2 = Region 
3 = Country / Territory 
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6.4 Appendix 6.4: Statistical Data Results for Cross-walk Meta-Analyses 
Table 7: Meta-Analysis Including All Studies with Prescription Opioid Nonmedical Use and 
Dependence Data 
Study Details         
 
RR LCI 95% HCI 
95% 
Weight 
(%) 
Back (2010), United States, age 12-99, year 2006 0.1327 0.1217 0.1447 7.4528 
Bassiony (2015), Egypt, age 12-99, year 2013 0.0556 0.0075 0.4123 0.2617 
Han (2015), United States, age 18-99, year 2003 0.1111 0.0977 0.1263 7.0217 
Han (2015), United States, age 18-99, year 2004 0.1176 0.1035 0.1337 7.0242 
Han (2015), United States, age 18-99, year 2005 0.1296 0.1151 0.1460 7.1294 
Han (2015), United States, age 18-99, year 2006 0.1207 0.1070 0.1361 7.1161 
Han (2015), United States, age 18-99, year 2007 0.1404 0.1254 0.1571 7.2000 
Han (2015), United States, age 18-99, year 2008 0.1509 0.1349 0.1689 7.2014 
Han (2015), United States, age 18-99, year 2009 0.1607 0.1445 0.1788 7.2626 
Han (2015), United States, age 18-99, year 2010 0.1636 0.1471 0.1820 7.2650 
Han (2015), United States, age 18-99, year 2011 0.1633 0.1459 0.1827 7.2004 
Han (2015), United States, age 18-99, year 2012 0.1786 0.1613 0.1977 7.3099 
Han (2015), United States, age 18-99, year 2013 0.1837 0.1648 0.2047 7.2436 
Martins (2010), United States, age 18-57, year 2001-02 0.2559 0.2107 0.3109 6.1687 
Saha (2016), United States, age 18-99, year 2012-13 0.2090 0.1858 0.2351 7.1424 
     
Pooled 0.15 0.14 0.17 100 
Statistics 
    
I-squared 90.8532 86.6097 93.7518 
 
Cochrane's Q 153.0582 
   
Chi2, p 0 
   
tau2 0.0360 
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Table 8: Meta-Analysis Without Egyptian (Bassiony 2015) Study Data 
Study         
 
RR LCI 95% HCI 
95% 
Weight 
(%) 
Back (2010), United States, age 12-99, year 2006 0.1327 0.1217 0.1447 7.4722 
Han (2015), United States, age 18-99, year 2003 0.1111 0.0977 0.1263 7.0401 
Han (2015), United States, age 18-99, year 2004 0.1176 0.1035 0.1337 7.0427 
Han (2015), United States, age 18-99, year 2005 0.1296 0.1151 0.1460 7.1481 
Han (2015), United States, age 18-99, year 2006 0.1207 0.1070 0.1361 7.1347 
Han (2015), United States, age 18-99, year 2007 0.1404 0.1254 0.1571 7.2189 
Han (2015), United States, age 18-99, year 2008 0.1509 0.1349 0.1689 7.2203 
Han (2015), United States, age 18-99, year 2009 0.1607 0.1445 0.1788 7.2816 
Han (2015), United States, age 18-99, year 2010 0.1636 0.1471 0.1820 7.2840 
Han (2015), United States, age 18-99, year 2011 0.1633 0.1459 0.1827 7.2193 
Han (2015), United States, age 18-99, year 2012 0.1786 0.1613 0.1977 7.3290 
Han (2015), United States, age 18-99, year 2013 0.1837 0.1648 0.2047 7.2626 
Martins (2010), United States, age 18-57, year 2001-
02 
0.2559 0.2107 0.3109 6.1853 
Saha (2016), United States, age 18-99, year 2012-13 0.2090 0.1858 0.2351 7.1612 
     
Pooled 0.15 0.14 0.17 100 
Statistics 
    
I-squared 91.4525 87.4073 94.1983 
 
Cochrane's Q 152.0920 
   
Chi2, p 0 
   
tau2 0.0360 
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Table 9: Meta-Analysis Without Egyptian (Bassiony 2015) Study Data and Only Most Recent Data 
from Han (2015) Study 
Study 
   
 
RR LCI 95% HCI 95% Weight (%) 
Back (2010), United States, age 12-99, year 
2006 
0.1327 0.1217 0.1447 25.8808 
Han (2015), United States, age 18-99, year 
2013 
0.1837 0.1648 0.2047 25.4932 
Martins (2010), United States, age 18-57, year 
2001-02 
0.2559 0.2107 0.3109 23.3242 
Saha (2016), United States, age 18-99, year 
2012-13 
0.2090 0.1858 0.2351 25.3018 
     
Pooled 0.19 0.14 0.25 100 
Statistics 
    
I-squared 95.1707 90.5944 97.5204 
 
Cochrane's Q 62.1205 
   
Chi2, p <0.001 
   
tau2 0.0702 
   
RR = risk ratio, LCI = lower confidence interval, HCI = higher confidence interval  
6.5 Appendix 6.5: PRISMA Checklist 
Section/topic  # Checklist item  
Reported 
from 
page  
TITLE   
Title  1 Identify the report as a systematic review, meta-analysis, or both.  3 
ABSTRACT   
Structured summary  2 Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, 
participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key 
findings; systematic review registration number.  
8 
INTRODUCTION   
Rationale  3 Describe the rationale for the review in the context of what is already known.  9- 
Objectives  4 Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, 
outcomes, and study design (PICOS).  
12 
METHODS   
Protocol and registration  5 Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration 
information including registration number.  
12- 
Eligibility criteria  6 Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, 
publication status) used as criteria for eligibility, giving rationale.  
12 
Information sources  7 Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional 
studies) in the search and date last searched.  
12 
Search  8 Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.  12 
Study selection  9 State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in 
the meta-analysis).  
13 
Data collection process  10 Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for 
obtaining and confirming data from investigators.  
14 
Data items  11 List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and 
simplifications made.  
14 
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Risk of bias in individual 
studies  
12 Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the 
study or outcome level), and how this information is to be used in any data synthesis.  
14 
Summary measures  13 State the principal summary measures (e.g., risk ratio, difference in means).  15 
Synthesis of results  14 Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) 
for each meta-analysis.  
15 
 
Risk of bias across studies  15 Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting 
within studies).  
14 
Additional analyses  16 Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which 
were pre-specified.  
15 
RESULTS   
Study selection  17 Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each 
stage, ideally with a flow diagram.  
17 
Study characteristics  18 For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide 
the citations.  
17 
Risk of bias within studies  19 Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).  17 
Results of individual studies  20 For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group 
(b) effect estimates and confidence intervals, ideally with a forest plot.  
17 
Synthesis of results  21 Present results of each meta-analysis done, including confidence intervals and measures of consistency.  19 
Risk of bias across studies  22 Present results of any assessment of risk of bias across studies (see Item 15).  19 
Additional analysis  23 Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]).  19 
DISCUSSION   
Summary of evidence  24 Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key 
groups (e.g., healthcare providers, users, and policy makers).  
41 
Limitations  25 Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified 
research, reporting bias).  
45 
Conclusions  26 Provide a general interpretation of the results in the context of other evidence, and implications for future research.  47 
FUNDING   
Funding  27 Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the 
systematic review.  
47 
